Chiral resolution of racemic n-protected cytisine

The resolution of N-protected (rac)-cytisine using chiral diaryl-tartaric acid in a solvent system addresses the synthesis challenge, achieving high enantiomeric purity and enabling a scalable production of (-)-cytisine for nicotine addiction therapy.

WO2026236680A1PCT designated stage Publication Date: 2026-11-12ACHIEVE LIFE SCIENCE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027395
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods for synthesizing enantiomerically pure (-)-cytisine are limited by the inability to resolve racemic mixtures of cytisine, leading to insufficient supply and accessibility of this compound for use as a nicotine addiction therapy.

Method used

A process involving the resolution of N-protected (rac)-cytisine using chiral diaryl-tartaric acid in a solvent system, followed by forming and isolating an enantiomerically enriched N-protected (-)-cytisine salt, such as N-protected (-)-cytisine dibenzoyl-L-tartrate.

Benefits of technology

The process achieves high enantiomeric purity of N-protected (-)-cytisine with enantiomeric excess ranging from 90% to 99.5%, providing a scalable synthetic route for (-)-cytisine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027395_12112026_PF_FP_ABST
    Figure US2026027395_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein is a process for preparing N-protected (-)-cytisine from N-protected (rac)-cytisine. The process includes resolving the N-protected (rac)-cytisine with a chiral acid to produce chiral N-protected cytisine with high chiral purity. The chiral N-protected cytisine may be in a salt or freebase form.
Need to check novelty before this filing date? Find Prior Art

Description

CHIRAL RESOLUTION OF RACEMIC N-PROTECTED CYTISINECROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Patent Application No.63 / 803,155, filed May 9, 2025, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Nicotine is an addictive substance that is rapidly absorbed during cigarette smoking which contributes to some 7 million premature deaths each year worldwide. Smoking is highly addictive, with more than 95% of unaided attempts at cessation failing to last 6 months. It has been estimated that for every year that a person continues smoking beyond his or her mid-30s, that person loses 3 months of life expectancy.

[0003] The pharmacotherapies currently available in the U.S. and Western Europe to help smokers stop include nicotine replacement therapy (NRT) and two non-nicotine containing medications: bupropion (Zyban®, Glaxo-SmithKline) and varenicline (Chantix@ / Champix®, Pfizer). NRT and bupropion appear to have about equal efficacy. Varenicline is more effective than single NRT and bupropion, although combination NRT is comparable in efficacy. An alternative to these commonly used pharmacotherapies is (-)-cytisine (International Union of Pure and Applied Chemistry (IUPAC) name: (1 R,5S)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-8H-pyrido[1 ,2a][1 ,5]diazocin-8-one; commonly referred to as cytisinicline, or simply as cytisine), which has been used for smoking cessation in Central and Eastern Europe for several decades commercialized as Tabex®.

[0004] As a natural plant alkaloid, (-)-cytisine may be isolated from various botanical sources such as, for example, from the plant genera Laburnum, Anagyris, Thermopsis, Cytisus, Genista and Sophora of the Faboideae family. Few multi-step syntheses of cytisine exist, and the resolution of racemic cytisine has not yet been achieved with suitable yields and enantiomeric purity. Accordingly, there exists a need for an efficient chemical synthesis of (-)-cytisine.SUMMARY

[0005] In some aspects, the present technology provides a process for preparing N-protected (-)-cytisine from N-protected (rac)-cytisine, the process comprising resolving the N-protected (rac)-cytisine with a chiral diaryl-tartaric acid.

[0006] In some aspects, the present technology provides compound prepared by resolving N-protected (rac)-cytisine with a chiral diaryl-tartaric acid, wherein the compound is N-protected (-)-cytisine.

[0007] In some aspects, the present technology provides process for resolving N-protected (rac)-cytisine, comprising combining N-protected (rac)-cytisine with a chiral diaryltartaric acid in a solvent system and forming N-protected (-)-cytisine.

[0008] In some aspects, the present technology provides an N-protected (-)-cytisine salt that is N-protected (-)-cytisine dibenzoyl-L-tartrate.

[0009] In some aspects, the present technology provides a process for improving the enantiomeric purity of a N-protected (-)-cytisine salt, comprising suspending the N-protected (-)-cytisine salt in a slurry solvent system to provide a N-protected (-)-cytisine salt slurry; mixing the N-protected (-)-cytisine salt slurry; and isolating an enantiomerically enriched N-protected (-)-cytisine salt from the slurry.

[0010] In some aspects, the present technology provides a process for preparing (1 R,5S)-N-benzylcytisine from N-benzyl-(rac)-cytisine, the process comprising resolving the N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

[0011] In some aspects, the present technology provides a (1 R,5S)-N-benzylcytisine salt prepared by resolving N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

[0012] In some aspects, the present technology provides a process for resolving N-benzyl-(rac)-cytisine, comprising: combining N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid in a solvent system; and forming (1 R,5S)-N-benzylcytisine.

[0013] In some aspects, the present technology provides an (1 R,5S)-N-benzylcytisine salt that is (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate.BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1 is a flowchart illustrating a process for preparing N-protected (-)-cytisine in accordance with the present technology.

[0015] FIG. 2A illustrates a chiral chromatograph, obtained by chiral liquid chromatography (LC) of (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate after isolation.

[0016] FIG. 2B illustrates a chiral chromatograph, obtained by chiral LC of (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate after recrystallization.DETAILED DESCRIPTION

[0017] (-)-Cytisine, a natural plant alkaloid found in several genera of the Faboideae family, including Laburnum, Anagyris, Thermopsis, Cytisus, Genista, Retama and Sophora, has recently demonstrated safety and efficacy as a nicotine addiction therapy in Phase I and II clinical trials. Currently, no scalable synthetic route exists for the chemical preparation of (-)-cytisine. Instead, (-)-cytisine is extracted from plant sources, thereby limiting the accessibility of (-)-cytisine for use as an active pharmaceutical ingredient (API). Extraction of natural products from raw materials like plant sources, while effective for obtaining enantiomerically pure compounds, is necessarily limited by the availability of the raw material, which in turn, limits the supply of the product in the market. On the other hand, supply is not a concern when chemical synthesis is employed, however, existing synthetic routes are limited by the inability to resolve racemic mixtures of cytisine (represented herein by “(rac)-cytisine” and “(±)-cytisine”), and as such, do not provide enantiomerically enriched (-)-cytisine.

[0018] The present technology generally relates to processes for preparing (-)-cytisine, which is also represented with absolute configuration as (1 R,5S)-cytisine, from (rac)-cytisine, or a derivative thereof. In particular, the (-)-cytisine may be prepared from a derivative of (rac)-cytisine, wherein the derivative is an N-protected derivative of cytisine, which is also referred to herein as “N-protected cytisine.” Accordingly, in some embodiments, the present technology provides a process for preparing N-protected (1 R,5S)-cytisine (also referred to herein simply as N-protected (-)-cytisine) from N-protected (rac)-cytisine. In such process, resolution of the N-protected (rac)-cytisine may be achieved using a chiral acid, such as, for example, a chiral tartaric acid.

[0019] Enantiomerically enriched compounds, including N-protected (-)-cytisine and (-)-cytisi ne, prepared from racemic mixtures in accordance with the present technology may exhibit high enantiomeric excess (ee). For example, N-protected (-)-cytisine having an ee of at least about 90%, at least about 92%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% may be provided by the processes disclosed herein.

[0020] While the present disclosure is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the present technology and is not intended to limit the present technology to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the present technology in any manner. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.Definitions

[0021] The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about.” It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term “about.”

[0022] The term “about,” as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of 10%, 5%, 1 %, 0.5%, or even 0.1% of the specified amount.

[0023] It is to be understood that such range format is used for convenience and brevity and should be understood flexibly to include numerical values explicitly specified as limits of a range, but also to include all individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly specified. Forexample, a ratio in the range of about 1 to about 200 should be understood to include the explicitly recited limits of about 1 and about 200, but also to include individual ratios such as about 2, about 3, and about 4, and sub-ranges such as about 10 to about 50, about 20 to about 100, and so forth. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.

[0024] Also, the disclosure of ranges is intended as a continuous range, including every value between the minimum and maximum values recited, as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and, in all instances, such ratios, ranges, and ranges of ratios represent various embodiments of the present disclosure.

[0025] “Comprising” or “comprises” is intended to mean that the formulations include the recited elements but not excluding others. “Consisting essentially of” when used to define formulations, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a cytisine formulation consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed present technology. “Consisting of” shall mean excluding more than trace elements of other ingredients. Embodiments defined by each of these transition terms are within the scope of this present technology.

[0026] “Enantiomeric ratio” or “er” refers to the ratio of a percent of one enantiomer present in a mixture to the percent of the other enantiomer present in the mixture. For example, a mixture having an enantiomeric ratio of 60:40 contains 60% of one enantiomer, e.g., the (-)-enantiomer, and 40% of the other enantiomer, e.g., the (-i-)-enantiomer. Likewise, a mixture having an enantiomeric ratio of 95:5 contains 95% of one enantiomer“enantiomerically enriched” and / or may be identified as having a high “enantiomeric excess (ee).” “Enantiomerically enriched” mixtures of the present technology include mixtures having an er of about 90:10 or higher.

[0027] The term “enantiomeric excess,” represented by “ee” or “% ee” herein, is used to describe how much more of one enantiomer is present in a mixture than the other. For example, a mixture having 60% of one enantiomer, e.g., the (-)-enantiomer, and 40% of the other enantiomer, e.g., the (+)-enantiomer, has an enantiomeric excess of 20, or 20% ee. Likewise, a mixture having a 95% of one enantiomer and 5% of the other enantiomer has 90% ee. A mixture having 50% of one enantiomer and 50% of the other enantiomer has no enantiomeric excess and is referred to herein as a “racemic mixture.” Enantiomerically enriched mixtures of the present technology include mixtures having at least about 80% ee.

[0028] The phrase “high enantiomeric excess” is used herein to refer to an enantiomeric excess of at least about 90%. For example, compounds of the present technology, such as, e.g., N-protected (-)-cytisine and (-)-cytisine, having a high enantiomeric excess may have from about 90% ee to about 99.9% ee.

[0029] Throughout the specification and claims, enantiomerically enriched derivatives and precursors that are prepared, isolated, or used in the processes described herein may be described usingor “(+)” descriptors (e.g., “N-benzyl-(-)-cytisine” or “N-benzyl-(-)-cytisine dibenzoyl tartrate”) to denote the absolute configuration relative to cytisine. Unless expressly indicated otherwise, such “(-)” / “(+)” descriptors are used for convenience to denote enantiomeric compounds that ultimately produce cytisine having the identified optical rotation, i.e., (-)-cytisine, which has absolute configuration (1 R,5S), or (+)-cytisine, which has the absolute configuration (1 S,5R).

[0030] As will be appreciated by those skilled in the art, specific rotation is an empirical property and the sign and magnitude observed for a given derivative, protected form, or salt may vary with structure and measurement conditions (including counterion, solvent, concentration, temperature, and wavelength) and therefore may not match the sign observed for the cytisine product itself (i.e., (-)-cytisine or (+)-cytisine). Accordingly, a derivative or salt described herein as “(-)” may exhibit a measured specific rotation that ispositive or negative under a given set of conditions, while still being enriched in the enantiomer that is configurationally correlated with (1 R,5S)-cytisine and that ultimately yields (-)-cytisine. Likewise, a derivative or salt described herein as “(+)” may exhibit a measured specific rotation that is positive or negative under a given set of conditions, while still being enriched in the enantiomer that is configurationally correlated with (1S,5R)-cytisine and that ultimately yields (+)-cytisine.

[0031] Where absolute configuration is stated for cytisine or for a derivative / precursor, the stated absolute configuration controls. For example, N-protected (-)-cytisine corresponds to N-protected (1 R,5S)-cytisine and N-protected (+)-cytisine corresponds to N-protected (1S,5R)-cytisine. Nonetheless, references to compounds using optical rotation (i.e., (-) or (+)) descriptors and / or absolute configuration (i.e., (1R,5S) or (1S,5R)) may be used interchangeably where consistent with the context. Typically, “(-)” / “(+)” descriptors are used for generic compounds, e.g., N-protected (-)-cytisine, and enantiomeric configuration is used for specific compounds, e.g., (1 R,5S)-N-benzylcytisine.

[0032] As noted above, the term “racemic” refers to a mixture having an equal amount of two enantiomers or a compound, i.e., an equal amount of the (-)-enantiomer and the (+)-enantiomer. Additionally, as used herein “racemic mixtures” may include any mixture having an enantiomeric ratio of less than 70:30 (or less than 40% ee). For example, a racemic mixture may have an enantiomeric ratio of about 50:50, about 51 :49, about 52:48, about 53:47, about 54:46, about 55:45, about 56:44, about 57:43, about 58:42, about 59:41 , about 60:40, about 65:35 or about 70:30. Further, a racemic mixture may have no enantiomeric excess, or an enantiomeric excess of about 5% ee, 10% ee, 15% ee, 20% ee, 25%, 30% ee, 35% ee, or 40% ee.Process for Preparing (-)-Cvtisine

[0033] In one aspect, the present technology relates to a process for preparing (-)-cytisine, or a derivative thereof. In some embodiments, the (-)-cytisine or derivative thereof produced by the process disclosed herein has a high enantiomeric excess. In some embodiments, the process is a process of preparing N-protected (-)-cytisine.

[0034] FIG. 1 is a flowchart illustrating a process 100 for preparing N-protected (-)-cytisine in accordance with the present technology. Process 100 begins by resolving N-protected (rac)-cytisine with a chiral acid 120. In particular, resolution of the N-protected (rac)-cytisine may be carried out with a chiral tartaric acid. In some embodiments, the chiral tartaric acid is a chiral diaryl tartaric acid. In further embodiments, the chiral diaryl tartaric acids is selected from (+)-dibenzoyl-D-tartaric acid, (-)-dibenzoyl-L-tartaric acid, (+)-di-p-toluoyl-D-tartaric acid and (-)-di-p-toluoyl-L-tartaric acid. In some embodiments, the chiral diaryl tartaric acid is (+)-dibenzoyl-D-tartaric acid. In some embodiments, the chiral diaryl tartaric acid is (-)-dibenzoyl-L-tartaric acid. In some embodiments, the chiral diaryl tartaric acid is (+)-di-p-toluoyl-D-tartaric acid. In some embodiments, the chiral diaryl tartaric acid is (-)-di-p-toluoyl-L-tartaric acid.

[0035] Notably, D-camphorsulfonic acid, which was reported to resolve (rac)-cytisine in E. van Tamelen and J. Baran, Total Synthesis of Oxygenated Lupin Alkaloids. J Am Chem Soc. 1958; 80(17), 4659-4670, was not found to be an effective chiral acid for use in the process of the present technology. Rather, attempts at resolution of N-protected (rac)-cytisine with D-camphorsulfonic acid resulted in low yielding oils with poor enantiomeric excess.

[0036] The N-protected (rac)-cytisine may include any nitrogen protecting group commonly used by those with skill in the relevant art. Nonlimiting examples of suitable nitrogen protecting groups include benzyl, triphenylmethyl, benzylidene, acetyl, trifluoroacetyl, fluorenylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc), carboxybenzyl (Cbz), and toluene sulfonyl (tosyl), among others. In some embodiments, the N-protected (rac)-cytisine includes a nitrogen protecting group selected from benzyl, acetyl, Fmoc, Boc, and Cbz. In further embodiments, the nitrogen protecting group is benzyl or Boc. In still further embodiments, the nitrogen protecting group is benzyl.

[0037] In some embodiments, the N-protected (rac)-cytisine is selected from N-benzyl-(rac)-cytisine (NBn-(rac)-cytisine), N-acetyl-(rac)-cytisine (NAc-(rac)-cytisine), N-tert-butoxycarbonyl-(rac)-cytisine (NBoc-(rac)-cytisine), N-fluorenylmethoxycarbonyl-(rac)-cytisine (NFmoc-(rac)-cytisine), and N-carboxybenzyl-(rac)-cytisine (NCbz-(rac)-cytisine). Infurther embodiments, the N-protected (rac)-cytisine is NBn-(rac)-cytisine or NBoc-(rac)-cytisine. In still further embodiments, the N-protected (rac)-cytisine is NBn-(rac)-cytisine.

[0038] Resolving the N-protected (rac)-cytisine with the chiral acid may include combining the N-protected (rac)-cytisine with the chiral acid in a solvent system. In some embodiments, the solvent system comprises one solvent. In some embodiments, the solvent system comprises more than one solvent. In some embodiments, the solvent system comprises two or more solvents. In some embodiments, the solvent system comprises a first solvent and a second solvent.

[0039] In some embodiments, the solvent system comprises a first solvent and a second solvent in a ratio of from about 1 :6 to about 6:1 by volume (first solvent:second solvent). In some embodiments, the ratio of the first solvent to the second solvent is from about 1 :5 to about 5:1 , about 1 :4 to about 4:1 , about 1 :3 to about 3:1 , about 1 :2 to about 2:1 , or about 1 :1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from about 1 :4 to about 6:1 , about 1 :1 to about 6:1 , about 2:1 to about 6:1 , about 3:1 to about 6:1 , or about 4:1 to about 6:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from about 1 :4 to about 5:1, about 1 :1 to about 5:1 , about 2:1 to about 5:1 , about 3:1 to about 5:1 , or about 4:1 to about 5:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from about 1 :1 to about 4:1 , about 2:1 to about 4:1 , or about 3:1 to about 4:1 by volume.

[0040] In some embodiments, the ratio of the first solvent to the second solvent is about 1 :6 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 1 :5 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 1 :4 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 1 :3 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 1 :2 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 1 :1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 2:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 3:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 4:1 by volume. In someembodiments, the ratio of the first solvent to the second solvent is about 5:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 6:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is about 4:1 by volume, such as about 12:3 by volume.

[0041] In some embodiments, the solvent system comprises a first solvent and a second solvent in a ratio of from 1 :6 to 6:1 by volume (first solvent:second solvent). In some embodiments, the ratio of the first solvent to the second solvent is from 1 :5 to 5:1 , 1 :4 to 4:1 , 1 :3 to 3:1 , 1 :2 to 2:1 , or 1 :1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from 1 :4 to 6:1 , 1 :1 to 6:1 , 2:1 to 6:1 , 3:1 to 6:1 , or 4:1 to 6:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from 1 :4 to 5:1 , 1 :1 to 5:1 , 2:1 to 5:1 , 3:1 to 5:1 , or 4:1 to 5:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is from 1 :1 to 4:1 , 2:1 to 4:1 , or 3:1 to 4:1 by volume.

[0042] In some embodiments, the ratio of the first solvent to the second solvent is 1 :6 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 1 :5 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 1 :4 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 1 :3 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 1 :2 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 1 :1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 2:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 3:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 4:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 5:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 6:1 by volume. In some embodiments, the ratio of the first solvent to the second solvent is 4:1 by volume, such as 12:3 by volume.

[0043] In some embodiments, the solvent system comprises a polar solvent. In some embodiments, the solvent system comprises one solvent and the solvent is a polar solvent. In some embodiments, the solvent system comprises more than one solvent and at leastone solvent is a polar solvent. In some embodiments, the solvent system comprises more than one solvent and each solvent is individually a polar solvent. In some embodiments, the solvent system comprises a first solvent and a second solvent, and each of the first and second solvents are polar solvents. Polar solvents included in the solvent system may be protic or aprotic. For instance, a polar solvent may be a polar protic solvent, like an alcohol, or a polar aprotic solvent, like a ketone. Suitable polar solvents for use in the solvent system include alcohol solvents, such as, methanol, ethanol, isopropanol, tert-butanol, pentanol, and the like, and ketone solvents, such as acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, cyclopentanone, and the like.

[0044] In some embodiments, the solvent system comprises acetone. In further embodiments, the solvent system comprises one solvent and the solvent is acetone.

[0045] In some embodiments, the solvent system comprises MEK. In further embodiments, the solvent system comprises one solvent and the solvent is MEK. In some embodiments, the solvent system further comprises MIBK. In further embodiments, the solvent system comprises a first solvent and a second solvent, where the first solvent is MEK and the second solvent is MIBK.

[0046] In some embodiments, the solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK). In some embodiments, the ratio of MEK to MIBK is from about 1 :5 to about 5:1 , about 1 :4 to about 4:1 , about 1 :3 to about 3:1 , about 1 :2 to about 2:1 , or about 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is from about 1 :4 to about 6:1 , about 1 :1 to about 6:1 , about 2:1 to about 6:1 , about 3:1 to about 6:1 , or about 4:1 to about 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is from about 1 :4 to about 5:1 , about 1 :1 to about 5:1 , about 2:1 to about 5:1 , about 3:1 to about 5:1 , or about 4:1 to about 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is from about 1 :1 to about 4:1 , about 2:1 to about 4:1 , or about 3:1 to about 4:1 by volume.

[0047] In some embodiments, the ratio of MEK to MIBK is about 1 :6 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :5 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :4 by volume. In some embodiments, the ratio of MEK toMIBK is about 1 :3 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :2 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is about 2:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 3:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 4:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 4:1 by volume, such as about 12:3 by volume.

[0048] In some embodiments, the solvent system comprises MEK and MIBK in a ratio of from 1 :6 to 6:1 by volume (MEK:MIBK). In some embodiments, the ratio of MEK to MIBK is from 1 :5 to 5:1 , 1 :4 to 4:1 , 1 :3 to 3:1 , 1 :2 to 2:1 , or 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :4 to 6:1 , 1 :1 to 6:1 , 2:1 to 6:1 , 3:1 to 6:1 , or 4:1 to 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :4 to 5:1 , 1 :1 to 5:1 , 2:1 to 5:1 , 3:1 to 5:1 , or 4:1 to 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :1 to 4:1 , 2:1 to 4:1 , or 3:1 to 4:1 by volume.

[0049] In some embodiments, the ratio of MEK to MIBK is 1 :6 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :5 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :4 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :3 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :2 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is 2:1 by volume. In some embodiments, the ratio of MEK to MIBK is 3:1 by volume. In some embodiments, the ratio of MEK to MIBK is 4:1 by volume. In some embodiments, the ratio of MEK to MIBK is 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is 4:1 by volume, such as 12:3 by volume.

[0050] When the N-protected (rac)-cytisine and chiral acid are combined in the solvent, the chiral acid may be present in an amount at least equal to that of the N-protected (rac)-cytisine. To achieve sufficient resolution, however, the chiral acid may be present in an amount at least slightly in excess of the amount of N-protected (rac)-cytisine. In particular,relative to 1.0 equivalent of N-protected (rac)-cytisine, the chiral acid may be present in about 0.5 equivalent to about 2.0 equivalents. In some embodiments, the chiral acid is present in about 0.3 equivalent to about 1.5 equivalents, about 0.3 equivalent to about 1.3 equivalents, about 0.3 equivalent to about 1.1 equivalents, about 0.3 equivalent to about 0.9 equivalents, or about 0.3 equivalent to about 0.7 equivalent. In some embodiments, the chiral acid is present in about 1.0 equivalent to about 1.8 equivalents, about 1.0 equivalent to about 1.6 equivalents, about 1.0 equivalent to about 1.4 equivalents, about 1.1 equivalents to about 1.7 equivalents, about 1.1 equivalents to about 1.5 equivalents, or about 1.1 equivalents to about 1.3 equivalents. In further embodiments, the chiral acid is present in about 1.2 equivalents.

[0051] In some embodiments, relative to 1.0 equivalent of N-protected (rac)-cytisine, the chiral acid is present in 0.3 equivalent to 1.5 equivalents, 0.3 equivalent to 1.3 equivalents, 0.3 equivalent to 1.1 equivalents, 0.3 equivalent to 0.9 equivalent, or 0.3 equivalent to 0.7 equivalent. In some embodiments, the chiral acid may be present in 1.0 equivalent to 2.0 equivalents. In some embodiments, the chiral acid is present in 1.0 equivalent to 1.8 equivalents, 1.0 equivalent to 1.6 equivalents, 1.0 equivalent to 1.4 equivalents, 1.1 equivalents to 1.7 equivalents, 1.1 equivalents to 1.5 equivalents, or 1.1 equivalents to 1.3 equivalents. In further embodiments, the chiral acid is present in 1.2 equivalents.

[0052] Analogously, the N-protected (rac)-cytisine and chiral acid may be combined in the solvent in a molar ratio of at least about 1 :1 , acid to N-protected (rac)-cytisine. In some embodiments, the N-protected (rac)-cytisine and chiral acid are present at a molar ratio of about 1 :1 to about 2:1, acid to N-protected (rac)-cytisine. For example, the N-protected (rac)-cytisine and chiral acid may be present at a molar ratio of about 1 :1 to about 1.9:1 , about 1 :1 to about 1.8:1 , about 1 :1 to about 1.7:1 , about 1 :1 to about 1.6:1 , about 1 :1 to about 1.5:1 , about 1 :1 to about 1.4:1 , about 1 :1 to about 1.3:1 , or about 1 :1 to about 1.2:1 , acid to N-protected (rac)-cytisine. In particular embodiments, the N-protected (rac)-cytisine and chiral acid are present at a molar ratio of about 1.2:1 , acid to N-protected (rac)-cytisine.

[0053] In some embodiments, the N-protected (rac)-cytisine and chiral acid are present at a molar ratio of 1 :1 to 2:1 , acid to N-protected (rac)-cytisine. For example, the N-protected (rac)-cytisine and chiral acid may be present at a molar ratio of 1 :1 to 1.9:1 , 1 :1 to 1.8:1 , 1 :1 to 1.7:1 , 1 :1 to 1.6:1 , 1 :1 to 1.5:1 , 1 :1 to 1.4:1 , 1 :1 to 1.3:1 , or 1 :1 to 1.2:1 , acid to N-protected (rac)-cytisine. In particular embodiments, the N-protected (rac)-cytisine and chiral acid are present at a molar ratio of 1.2:1 , acid to N-protected (rac)-cytisine.

[0054] As will be appreciated, resolution of a basic compound with a chiral acid is achieved by forming a stable crystalline complex of the basic compound and the chiral acid, i.e. , by forming a salt or a co-crystal, collectively referred to herein using the term “salt.” As such, combination of the N-protected (rac)-cytisine with the chiral acid yields a chiral N-protected cytisine salt, namely, a N-protected (1 R,5S)-cytisine salt (also referred to herein simply as N-protected (-)-cytisine salt) or a N-protected (1S,5R)-cytisine salt (also referred to herein simply as N-protected (+)-cytisine salt), depending on the chiral acid used in the resolution. In some embodiments, the chiral N-protected cytisine salt forms quickly, i.e., precipitation begins within 10 minutes, after combining the N-protected (rac)-cytisine with the chiral acid. In such embodiments, combining the N-protected (rac)-cytisine with the chiral acid includes stirring the combination at ambient conditions until the chiral salt precipitates out of the solution. In some embodiments, the combination is stirred at ambient conditions overnight, such as for about 6 hours to about 18 hours. In some embodiments, the combination is stirred at ambient conditions for about 6 hours to about 16 hours, about 6 hours to about 14 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 8 hours to about 18 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 8 hours to about 12 hours, or about 8 hours to about 10 hours, about 10 hours to about 18 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 18 hours, about 12 hours to about 16 hours, or about 12 hours to about 14 hours.

[0055] In some embodiments, the combination is stirred at ambient conditions for 6 hours to 18 hours. In some embodiments, the combination is stirred at ambient conditions for 6 hours to 16 hours, 6 hours to 14 hours, 6 hours to 12 hours, 6 hours to 10 hours, 8hours to 18 hours, 8 hours to 16 hours, 8 hours to 14 hours, 8 hours to 12 hours, or 8 hours to 10 hours, 10 hours to 18 hours, 10 hours to 16 hours, 10 hours to 14 hours, 10 hours to 12 hours, 12 hours to 18 hours, 12 hours to 16 hours, or 12 hours to 14 hours.

[0056] Alternatively, in some embodiments, formation of the chiral N-protected cytisine salt is more difficult to achieve. Thus, combining the N-protected (rac)-cytisine with the chiral acid may include stirring the combination at an elevated temperature for a period of time sufficient to form the chiral salt. In some embodiments, the combination is stirred at a temperature of about 30 °C to about 95 °C. For example, the combination may be stirred at a temperature of about 40 °C to about 95 °C, about 50 °C to about 90 °C, about 60 °C to about 85 °C, or about 70 °C to about 80 °C. In some embodiments, the combination is stirred at a temperature of about 50 °C to about 95 °C, about 60 °C to about 95 °C, about 70 °C to about 95 °C, about 80 °C to about 95 °C, about 60 °C to about 90 °C, about 70 °C to about 90 °C, about 80 °C to about 90 °C, about 65 °C to about 85 °C, about 70 °C to about 85 °C, about 75 °C to about 85 °C, or about 80 °C to about 85 °C. Alternatively, in some embodiments, the combination is stirred at a temperature of about 30 °C to about 60 °C, about 30 °C to about 50 °C, about 30 °C to about 40 °C, about 40 °C to about 70 °C, about 40 °C to about 60 °C, about 40 °C to about 50 °C, about 50 °C to about 70 °C, or about 50 °C to about 60 °C. In some embodiments, the combination is stirred at a temperature of about 30 °C, about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, about 85 °C, about 90 °C, or about 95 °C. In some embodiments, the combination is stirred at a temperature of about 85 °C.

[0057] In some embodiments, the combination is stirred at a temperature of 30 °C to 95 °C. For example, the combination may be stirred at a temperature of 40 °C to 95 °C, 50 °C to 90 °C, 60 °C to 85 °C, or 70 °C to 80 °C. In some embodiments, the combination is stirred at a temperature of 50 °C to 95 °C, 60 °C to 95 °C, 70 °C to 95 °C, 80 °C to 95 °C, 60 °C to 90 °C, 70 °C to 90 °C, 80 °C to 90 °C, 65 °C to 85 °C, 70 °C to 85 °C, 75 °C to 85 °C, or 80 °C to 85 °C. Alternatively, in some embodiments, the combination is stirred at a temperature of 30 °C to 60 °C, 30 °C to 50 °C, 30 °C to 40 °C, 40 °C to 70 °C, 40 °C to60 °C, 40 °C to 50 °C, 50 °C to 70 °C, or 50 °C to 60 °C. In particular embodiments, the combination is stirred at a temperature of 30 °C, 35 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C, 75 °C, 80 °C, 85 °C, 90 °C, or 95 °C. In some embodiments, the combination is stirred at a temperature of 85 °C.

[0058] When heating is required to facilitate formation of the chiral N-protected cytisine salt, the combination may be stirred at elevated temperature overnight, such as for about 10 minutes to about 18 hours. In some embodiments, the combination is stirred at elevated temperature for about 10 minutes to about 6 hours, about 10 minutes to about 4 hours, about 10 minutes to about 2 hours, about 10 minutes to about 1 hour, about 30 minutes to about 6 hours, about 30 minutes to about 4 hours, about 30 minutes to about 2 hours, or about 30 minutes to about 1 hour. In some embodiments, the combination is stirred at elevated temperature for about 1 hour to about 6 hours, about 1 hour to about 4 hours, about 1 hour to about 2 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, or about 4 hours to about 6 hours. In some embodiments, the combination is stirred at elevated temperature for about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, or about 6 hours. In some embodiments, the combination is stirred at elevated temperature for about 30 minutes.

[0059] In some embodiments, the combination is stirred at elevated temperature for about 6 hours to about 16 hours, about 6 hours to about 14 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 8 hours to about 18 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 8 hours to about 12 hours, or about 8 hours to about 10 hours, about 10 hours to about 18 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 18 hours, about 12 hours to about 16 hours, or about 12 hours to about 14 hours.

[0060] In some embodiments, the combination is stirred at elevated temperature for 10 minutes to 18 hours. In some embodiments, the combination is stirred at elevated temperature for 10 minutes to 6 hours, 10 minutes to 4 hours, 10 minutes to 2 hours, 10 minutes to 1 hour, 30 minutes to 6 hours, 30 minutes to 4 hours, 30 minutes to 2 hours, or 30 minutes to 1 hour. In some embodiments, the combination is stirred at elevated temperature for 1 hour to 6 hours, 1 hour to 4 hours, 1 hour to 2 hours, 2 hours to 6 hours, 2 hours to 4 hours, or 4 hours to 6 hours. In some embodiments, the combination is stirred at elevated temperature for 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, or 6 hours. In some embodiments, the combination is stirred at elevated temperature for 30 minutes. In some embodiments, the combination is stirred at elevated temperature for 6 hours to 16 hours, 6 hours to 14 hours, 6 hours to 12 hours, 6 hours to 10 hours, 8 hours to 18 hours, 8 hours to 16 hours, 8 hours to 14 hours, 8 hours to 12 hours, or 8 hours to 10 hours, 10 hours to 18 hours, 10 hours to 16 hours, 10 hours to 14 hours, 10 hours to 12 hours, 12 hours to 18 hours, 12 hours to 16 hours, or 12 hours to 14 hours.

[0061] As previously noted, the identity of the chiral N-protected cytisine salt formed by resolving the N-protected (rac)-cytisine depends on the chiral acid used to achieve the resolution. Specifically, both the counterion and the chirality of the N-protected salt are dependent on the identity of the chiral acid. For example, if the chiral acid is a (-)-diaryl tartaric acid, then the chiral salt is an N-protected (-)-cytisine diaryl tartrate, whereas if the chiral acid is a (-i-)-diaryl tartaric acid, then the chiral salt is an N-protected (+)-cytisine diaryl tartrate. Accordingly, in some embodiments, the chiral acid is (-)-dibenzoyl-L-tartaric acid or (-)-di-p-toluoyl-L-tartaric acid and the N-protected cytisine salt is a N-protected (-)-cytisine salt. In further embodiments, the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate or N-protected (-)-cytisine di-p-toluoyl-L-tartrate. In other embodiments, the chiral acid is (+)-dibenzoyl-D-tartaric acid or (+)-di-p-toluoyl-D-tartaric acid and the N-protected cytisine salt is a N-protected (+)-cytisine salt. In further embodiments, the N-protected (+)-cytisine salt is N-protected (+)-cytisine dibenzoyl-D-tartrate or N-protected (+)-cytisine di-p-toluoyl-D-tartrate.

[0062] Notably, unlike other chiral resolution processes, in process 100 resolving the N-protected (rac)-cytisine does not require seeding the solution containing the N-protected (rac)-cytisine and chiral acid to achieve the resolution. Generally, seeding includes adding a seed crystal of the desired enantiomer to a racemic mixture to facilitate chiral resolution of that enantiomer. Thus, processes that require seeding to achieve resolution of a racemic mixture may use a considerable amount (e.g., 10 mol% or more) of pure enantiomer prepared from a prior resolution process, thereby reducing the amount of the pure enantiomer that may be used downstream produced by each resolution. Such reduced usable yield is avoided in the process of the present technology, at least in part because no seed crystal is needed to resolve the N-protected (rac)-cytisine.

[0063] Seeding is also commonly used in crystallization processes to control particle size and / or solid-state form of the resulting crystals. Accordingly, in some embodiments, process 100 includes seeding the combination to control the particle size and structure of the precipitated chiral N-protected cytisine. When used for crystallization control, only a small amount (e.g., less than 5 mol%) of the seed crystal is typically needed. Therefore, when process 100 includes seeding, the seed crystal may be added to the combination in an amount of about 0.1 mol% to about 5 mol%. In some embodiments, the seed crystal is added to the combination in an amount of about 0.1 mol% to about 3 mol%, about 0.5 mol% to about 5 mol%, about 0.5 mol% to about 3 mol%, about 0.1 mol% to about 1 mol%, or about 0.5 mol% to about 1 mol%.

[0064] In some embodiments, the seed crystal may be added to the combination in an amount of 0.1 mol% to 5 mol%. In some embodiments, the seed crystal is added to the combination in an amount of 0.1 mol% to 3 mol%, 0.5 mol% to 5 mol%, 0.5 mol% to 3 mol%, 0.1 mol% to 1 mol%, or 0.5 mol% to 1 mol%.

[0065] In some embodiments, the seed crystal is a N-protected (-)-cytisine salt. In some embodiments, the seed crystal is N-protected (-)-cytisine diaryl tartrate. In some embodiments, the seed crystal is N-protected (-)-cytisine dibenzoyl tartrate. In some embodiments, the seed crystal is (1 R,5S)-N-benzylcytisine dibenzoyl tartrate.

[0066] In some embodiments, the seed crystal is a N-protected (+)-cytisine salt. In some embodiments, the seed crystal is N-protected (+)-cytisine diaryl tartrate. In some embodiments, the seed crystal is N-protected (+)-cytisine dibenzoyl tartrate. In some embodiments, the seed crystal is (1 S,5R)-N-benzylcytisine dibenzoyl tartrate.

[0067] In some embodiments, the combination is cooled from the elevated temperature to an intermediate temperature before the seed crystal is added. For example, in some embodiments, the combination is cooled to an intermediate temperature about 1 °C to about 20 °C, about 2 °C to about 15 °C, or about 5 °C to about 12 °C below the elevated temperature before the seed crystal is added. In some embodiments, the combination is cooled to an intermediate temperature about 2 °C, about 5 °C, about 8 °C, about 10 °C, about 12 °C, or about 15 °C below the elevated temperature before the seed crystal is added.

[0068] In some embodiments, the combination is cooled to an intermediate temperature 1 °C to 20 °C, 2 °C to 15 °C, or 5 °C to 12 °C below the elevated temperature before the seed crystal is added. In some embodiments, the combination is cooled to an intermediate temperature 2 °C, 5 °C, 8 °C, 10 °C, 12 °C, or 15 °C below the elevated temperature before the seed crystal is added.

[0069] In some embodiments, the combination is cooled to an intermediate temperature of about 25 °C to about 80 °C. For example, the combination may be cooled to an intermediate temperature of about 30 °C to about 80 °C, about 40 °C to about 80 °C, about 50 °C to about 80 °C, about 60 °C to about 80 °C, or about 70 °C to about 80 °C. In some embodiments, the combination is cooled to an intermediate temperature of about 25 °C to about 75 °C, about 30 °C to about 75 °C, about 40 °C to about 75 °C, about 50 °C to about 75 °C, about 60 °C to about 75 °C, or about 65 °C to about 75 °C. In some embodiments, the combination is cooled to an intermediate temperature of about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, or about 80 °C. In some embodiments, the combination is cooled to an intermediate temperature of about 75 °C prior to seeding.

[0070] In some embodiments, the combination is cooled to an intermediate temperature of 25 °C to 80 °C. For example, the combination may be cooled to an intermediate temperature of 30 °C to 80 °C, 40 °C to 80 °C, 50 °C to 80 °C, 60 °C to 80 °C, or 70 °C to 80 °C. In some embodiments, the combination is cooled to an intermediate temperature of 25 °C to 75 °C, 30 °C to 75 °C, 40 °C to 75 °C, 50 °C to 75 °C, 60 °C to 75 °C, or 65 °C to 75 °C. In some embodiments, the combination is cooled to an intermediate temperature of 25 °C, 30 °C, 35 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C, 75 °C, or 80 °C. In some embodiments, the combination is cooled to an intermediate temperature of 75 °C prior to seeding.

[0071] In some embodiments, the elevated temperature is about 85 °C and the combination is cooled to about 75 °C prior to seeding. In some embodiments, the elevated temperature is 85 °C and the combination is cooled to 75 °C prior to seeding.

[0072] In some embodiments, after seeding, or, if no seed crystal is added to the combination, after stirring at an elevated temperature is complete, the combination is cooled to a low temperature, such as a temperature of about -10 °C to about 35 °C, about -5 °C to about 30 °C, or about 0 °C to about 25 °C. In some embodiments, the combination is cooled to a temperature of about -5 °C, about -2 °C, about 0 °C, about 2 °C, about 5 °C, about 7 °C, about 10 °C, about 15 °C, about 20 °C, or about 25 °C. In some embodiments, the combination is cooled to a temperature of about 0 °C.

[0073] In some embodiments, the combination is cooled to a temperature of -10 °C to 35 °C, -5 °C to 30 °C, or 0 °C to 25 °C. In some embodiments, the combination is cooled to a temperature of -5 °C, -2 °C, 0 °C, 2 °C, 5 °C, 7 °C, 10 °C, 15 °C, 20 °C, or 25 °C. In some embodiments, the combination is cooled to a temperature of 0 °C.

[0074] In some embodiments, the combination is cooled at a rate of about 0.1 °C / min to about 2 °C / min, from about 0.1 °C / min to about 1.5 °C / min, from about 0.1 °C / min to about 1 °C / min, or from about 0.1 °C / min to about 0.5 °C / min. In some embodiments, the combination is cooled at a rate of about 0.1 °C / min, about 0.2 °C / min, about 0.3 °C / min, about 0.4 °C / min, about 0.5 °C / min, about 0.6 °C / min, about 0.7 °C / min, or about 0.8 °C / min. In some embodiments, the combination is cooled at a rate of about 0.3 °C / min.

[0075] In some embodiments, the combination is cooled at a rate of 0.1 °C / min to 2 °C / min, from 0.1 °C / min to 1.5 °C / min, from 0.1 °C / min to 1 °C / min, or from 0.1 °C / min to 0.5 °C / min. In some embodiments, the combination is cooled at a rate of 0.1 °C / min, 0.2 °C / min, 0.3 °C / min, 0.4 °C / min, 0.5 °C / min, 0.6 °C / min, 0.7 °C / min, or 0.8 °C / min. In some embodiments, the combination is cooled at a rate of 0.3 °C / min.

[0076] In some embodiments, after the seeded or unseeded combination has cooled, the combination is subjected to a ripening process to promote crystal growth and improve the particle size distribution and solid-state form of the precipitated chiral N-protected cytisine salt. In some embodiments, ripening comprises one or more heating and cooling cycles. In some embodiments, ripening comprises at least 2, at least 3, at least 4, or at least 5 heating and cooling cycles. In some embodiments, ripening comprises 2 heating and cooling cycles. In some embodiments, each heating and cooling cycle comprises heating the combination to an elevated temperature and then cooling the combination to a low temperature. In some embodiments, the elevated temperature is from about 30 °C to about 95 °C, such as any of the elevated temperatures or ranges described with respect to heating the combination of N-protected (rac)-cytisine and the chiral acid. In some embodiments, the elevated temperature during ripening is about 65 °C. In some embodiments, the elevated temperature during ripening is 65 °C.

[0077] In some embodiments, the combination is held at the elevated temperature during ripening for about 1 minute to about 60 minutes. For example, the combination may be held at the elevated temperature for about 1 minute to about 45 minutes, about 1 minute to about 30 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 30 minutes, or about 15 minutes to about 30 minutes. In some embodiments, the combination is held at the elevated temperature for about 5 minutes to about 25 minutes, about 5 minutes to about 20 minutes, about 5 minutes to about 15 minutes, or about 5 minutes to about 10 minutes. In some embodiments, the combination is held at the elevated temperature for about 10 minutes to about 25 minutes, about 10 minutes to about 20 minutes, or about 10 minutes to about 15 minutes. In some embodiments, the combination is held at the elevatedtemperature for about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, or about 30 minutes.

[0078] In some embodiments, the combination is held at the elevated temperature during ripening for 1 minute to 60 minutes. For example, the combination may be held at the elevated temperature for 1 minute to 45 minutes, 1 minute to 30 minutes, 5 minutes to 30 minutes, 10 minutes to 30 minutes, or 15 minutes to 30 minutes. In some embodiments, the combination is held at the elevated temperature for 5 minutes to 25 minutes, 5 minutes to 20 minutes, 5 minutes to 15 minutes, or 5 minutes to 10 minutes. In some embodiments, the combination is held at the elevated temperature for 10 minutes to 25 minutes, 10 minutes to 20 minutes, or 10 minutes to 15 minutes. In some embodiments, the combination is held at the elevated temperature for 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes.

[0079] In some embodiments, after heating to the elevated temperature, the ripening process includes cooling the combination to a low temperature of about -10 °C to about 35 °C, such as any of the elevated temperatures or ranges described with respect to cooling the seeded or unseeded combination. In some embodiments, the combination is cooled to a temperature of about 0 °C. In some embodiments, the combination is cooled to a temperature of 0 °C.

[0080] In some embodiments, after cooling to the low temperature, the combination is held at that temperature for a period of time before the next heating step. In some embodiments, the combination is held at the low temperature for about 10 minutes to about 120 minutes, about 15 minutes to about 90 minutes, about 20 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In some embodiments, the combination is held at the low temperature for about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 45 minutes, about 60 minutes, or about 90 minutes. In some embodiments, the combination is held at the low temperature for about 30 minutes between heating and cooling cycles. In some embodiments, the combination is held at the low temperature for about 1 hour or more following the final heating and cooling cycle to complete crystallization.

[0081] In some embodiments, the combination is held at the low temperature for 10 minutes to 120 minutes, 15 minutes to 90 minutes, 20 minutes to 60 minutes, or 25 minutes to 45 minutes. In some embodiments, the combination is held at the low temperature for 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes, 60 minutes, or 90 minutes. In some embodiments, the combination is held at the low temperature for 30 minutes between heating and cooling cycles. In some embodiments, the combination is held at the low temperature for 1 hour or more following the final heating and cooling cycle.

[0082] In some embodiments, the rate of cooling during each heating and cooling cycle is from about 0.1 °C / min to about 2 °C / min, from about 0.1 °C / min to about 1.5 °C / min, from about 0.1 °C / min to about 1 °C / min, or from about 0.1 °C / min to about 0.5 °C / min. In some embodiments, the rate of cooling during each heating and cooling cycle is about 0.1 °C / min, about 0.2 °C / min, about 0.3 °C / min, about 0.4 °C / min, about 0.5 °C / min, about 0.6 °C / min, about 0.7 °C / min, or about 0.8 °C / min. In some embodiments, the rate of cooling during each heating and cooling cycle is about 0.2 °C / min.

[0083] In some embodiments, the rate of cooling during each heating and cooling cycle is from 0.1 °C / min to 2 °C / min, from 0.1 °C / min to 1.5 °C / min, from 0.1 °C / min to 1 °C / min, or from 0.1 °C / min to 0.5 °C / min. In some embodiments, the rate of cooling during each heating and cooling cycle is 0.1 °C / min, 0.2 °C / min, 0.3 °C / min, 0.4 °C / min, 0.5 °C / min, 0.6 °C / min, 0.7 °C / min, or 0.8 °C / min. In some embodiments, the rate of cooling during each heating and cooling cycle is 0.2 °C / min.

[0084] In some embodiments, the combination is agitated, such as by stirring, during ripening to promote uniform crystal growth.

[0085] After the chiral N-protected cytisine salt is formed and precipitated out of solution, process 100 includes isolating N-protected (-)-cytisine at step 140. The N-protected (-)-cytisine may be isolated according to techniques known in the art including, but not limited to filtration, crystallization, chromatography, recrystallization, and extraction. The particular techniques used for isolation may vary based on the chiral N-protected cytisine salt that was produced by resolution of N-protected (rac)-cytisine with the chiral acid.

[0086] In some embodiments, isolating the N-protected (-)-cytisine includes removing the chiral N-protected cytisine salt from the solution. In some embodiments, the solution is decanted from the precipitated salt. In other embodiments, the salt is filtered from the solution. Once removed from the solution, the chiral N-protected salt may be washed according to commonly used techniques. In some embodiments, the chiral N-protected salt is washed with the solvent used in step 120, such as, for example, methanol, ethanol, isopropanol, tert-butanol, pentanol, acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, and cyclopentanone, among others. In further embodiments, the chiral N-protected cytisine salt is washed with acetone or MEK.

[0087] In some embodiments, the isolated N-protected (-)-cytisine salt is dried to remove residual solvent. The drying may be carried out by any method suitable for drying solid pharmaceutical intermediates, including, for example, drying under vacuum, drying under a stream of inert gas such as nitrogen, air drying, or a combination thereof. In some embodiments, the isolated salt is dried under vacuum. In some embodiments, the isolated salt is dried at a temperature of about 20 °C to about 60 °C, about 30 °C to about 55 °C, or about 35 °C to about 45 °C. In some embodiments, the isolated salt is dried at a temperature of about 20 °C, about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, or about 60 °C. In some embodiments, the isolated salt is dried under vacuum at a temperature of about 40 °C. In some embodiments, the isolated salt is dried until a target loss on drying is achieved.

[0088] In some embodiments, the chiral N-protected cytisine salt is a N-protected (+)-cytisine salt. As will be appreciated, when a racemic mixture of a compound is treated with a chiral acid, only one enantiomer of the mixture interacts with the acid to form a chiral salt, and the other enantiomer remains in solution as a freebase. Thus, when the N-protected (+)-cytisine salt is removed from the solution, the N-protected (-)-cytisine remains in a freebase form. Accordingly, in some embodiments, the N-protected (-)-cytisine is obtained by crystallization from the solution. For example, when the chiral N-protected cytisine salt is filtered from the solution, the N-protected (-)-cytisine remains in the filtrate and is subsequently crystallized therefrom.

[0089] Alternatively, the chiral N-protected cytisine salt may be a N-protected (-)-cytisine salt. In some embodiments, the N-protected (-)-cytisine is in a salt form. Thus, in such embodiments, the N-protected (-)-cytisine is isolated by removing the chiral N-protected salt from the solution, as described above. In other embodiments, however, the N-protected (-)-cytisine is in the freebase form. In such embodiments, isolating the N-protected (-)-cytisine includes transforming the N-protected (-)-cytisine salt to N-protected (-)-cytisine in the freebase form. Such transformation may be carried out by any method known in the art that is suitable for basifying chiral salts.

[0090] Accordingly, after isolating, the N-protected (-)-cytisine may be an N-protected (-)-cytisine salt or a freebase N-protected (-)-cytisine. In some embodiments, the N-protected (-)-cytisine is an N-protected (-)-cytisine salt. In further embodiments, the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate, N-protected (-)-cytisine dibenzoyl-D-tartrate, N-protected (-)-cytisine di-p-toluoyl-L-tartrate, N-protected (-)-cytisine or di-p-toluoyl-D-tartrate. In still further embodiments, the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate or N-protected (-)-cytisine dibenzoyl-D-tartrate.

[0091] In some embodiments, the N-protected (-)-cytisine salt is selected from N-benzyl-(-)-cytisine salt, (NBn-(-)-cytisine salt), N-acetyl-(-)-cytisine salt (NAc-(-)-cytisine salt), N-tert-butoxycarbonyl-(-)-cytisine salt (NBoc-(-)-cytisine salt), N-fluorenylmethoxycarbonyl-(-)-cytisine salt (NFmoc-(-)-cytisine salt), and N-carboxybenzyl-(-)-cytisine salt (NCbz-(-)-cytisine salt). In further embodiments, the N-protected (-)-cytisine salt is an NBn-(-)-cytisine salt or an NBoc-(-)-cytisine salt. In still further embodiments, the N-protected (-)-cytisine salt is selected from NBn-(-)-cytisine dibenzoyl-L-tartrate, NBn-(-)-cytisine di-p-toluoyl-L-tartrate, NBn-(+)-cytisine dibenzoyl-D-tartrate, NBn-(+)-cytisine di-p-toluoyl-D-tartrate, NBoc-(-)-cytisine dibenzoyl-L-tartrate, NBoc-(-)-cytisine di-p-toluoyl-L-tartrate, NBoc-(+)-cytisine dibenzoyl-D-tartrate, NBoc-(+)-cytisine di-p-toluoyl-D-tartrate. In yet further embodiments, the N-protected (-)-cytisine salt is NBn-(-)-cytisine dibenzoyl-L-tartrate or NBn-(+)-cytisine dibenzoyl-D-tartrate. In other further embodiments, the N-protected (-)-cytisine salt is NBoc-(-)-cytisine dibenzoyl-L-tartrate or NBoc-(+)-cytisine dibenzoyl-D-tartrate.

[0092] Alternatively, in some embodiments, the N-protected (-)-cytisine is freebase N-protected (-)-cytisine. In further embodiments, the N-protected (-)-cytisine is selected from N-benzyl-(-)-cytisine (NBn-(-)-cytisine), N-acetyl-(-)-cytisine (NAc-(-)-cytisine), N-tert-butoxycarbonyl-(-)-cytisine (NBoc-(-)-cytisine), N-fluorenylmethoxycarbonyl-(-)-cytisine (NFmoc-(-)-cytisine), and N-carboxybenzyl-(-)-cytisine (NCbz-(-)-cytisine). In still further embodiments, the N-protected (-)-cytisine is NBn-(-)-cytisine or NBoc-(-)-cytisine. In some embodiments, the N-protected (-)-cytisine is NBn-(-)-cytisine. In other embodiments, the N-protected (-)-cytisine is NBoc-(-)-cytisine.

[0093] The isolated N-protected (-)-cytisine, in salt or freebase form, may have a high enantiomeric excess. In particular, N-protected (-)-cytisine prepared according to the present technology may have an enantiomeric excess (ee) of at least about 90%. In some embodiments, the N-protected (-)-cytisine has an ee of about 90% to about 96%, about 91 % to about 96%, about 92% to about 96%, about 93% to about 96%, about 94% to about 96%, or about 95% to about 96%. In further embodiments, the N-protected (-)-cytisine has an ee of about 95%, about 95.1%, about 95.2%, about 95.3%, about 95.4%, about 95.5%, about 95.6%, about 95.7%, about 95.8%, about 95.9%, or about 96%.

[0094] In some embodiments, the N-protected (-)-cytisine is in freebase form and has an enantiomeric excess (ee) of at least about 90%. In some embodiments, the N-protected (-)-cytisine is in freebase form and an ee of about 90% to about 96%, about 91% to about 96%, about 92% to about 96%, about 93% to about 96%, about 94% to about 96%, or about 95% to about 96%. In further embodiments, the N-protected (-)-cytisine is in freebase form and has an ee of about 95%, about 95.1%, about 95.2%, about 95.3%, about 95.4%, about 95.5%, about 95.6%, about 95.7%, about 95.8%, about 95.9%, or about 96%.

[0095] In some embodiments, the N-protected (-)-cytisine is in salt form and has an enantiomeric excess (ee) of at least about 90%. In some embodiments, the N-protected (-)-cytisine is in salt form and an ee of about 90% to about 96%, about 91 % to about 96%, about 92% to about 96%, about 93% to about 96%, about 94% to about 96%, or about 95% to about 96%. In further embodiments, the N-protected (-)-cytisine is in salt form and has anee of about 95%, about 95.1%, about 95.2%, about 95.3%, about 95.4%, about 95.5%, about 95.6%, about 95.7%, about 95.8%, about 95.9%, or about 96%.

[0096] In some embodiments, N-protected (-)-cytisine has an enantiomeric excess (ee) of at least 90%. In some embodiments, the N-protected (-)-cytisine has an ee of 90% to 96%, 91% to 96%, 92% to 96%, 93% to 96%, 94% to 96%, or 95% to 96%. In further embodiments, the N-protected (-)-cytisine has an ee of 95%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, or 96%.

[0097] In some embodiments, the N-protected (-)-cytisine is in freebase form and has an enantiomeric excess (ee) of at least 90%. In some embodiments, the N-protected (-)-cytisine is in freebase form and an ee of 90% to 96%, 91% to 96%, 92% to 96%, 93% to 96%, 94% to 96%, or 95% to 96%. In further embodiments, the N-protected (-)-cytisine is in freebase form and has an ee of 95%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, or 96%.

[0098] In some embodiments, the N-protected (-)-cytisine is in salt form and has an enantiomeric excess (ee) of at least 90%. In some embodiments, the N-protected (-)-cytisine is in salt form and an ee of 90% to 96%, 91% to 96%, 92% to 96%, 93% to 96%, 94% to 96%, or 95% to 96%. In further embodiments, the N-protected (-)-cytisine is in salt form and has an ee of 95%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, or 96%.

[0099] Process 100 may optionally include, after isolating the N-protected (-)-cytisine, purifying the N-protected (-)-cytisine at step 160 to achieve a higher chiral purity. In general, the N-protected (-)-cytisine may be purified by first suspending the N-protected (-)-cytisine in a slurry solvent system to provide an N-protected (-)-cytisine slurry and then mixing the N-protected (-)-cytisine slurry. In some embodiments, all or a portion of the N-protected (-)-cytisine remains suspended in the slurry solvent system during mixing. In other embodiments, all or a portion of the N-protected (-)-cytisine dissolves in the slurry solvent system during mixing, thereby providing an N-protected (-)-cytisine solution. The combination of N-protected (-)-cytisine and the slurry solvent are collectively referred to herein as a “slurry”, but all forms of the combination, including, for example, slurries,suspensions, and solutions, are envisioned and may be present during any portion of the purification (step 106). The slurry solvent system may be the same as or different from the solvent system used in the resolution step. In some embodiments, the slurry solvent system comprises one slurry solvent. In some embodiments, the slurry solvent system comprises more than one slurry solvent. In some embodiments, the slurry solvent system comprises two or more slurry solvents. In some embodiments, the slurry solvent system comprises a first slurry solvent and a second slurry solvent.

[0100] In some embodiments, the slurry solvent system comprises a first slurry solvent and a second slurry solvent in a ratio of from about 1 :6 to about 6:1 by volume (first slurry solvent:second slurry solvent). In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from about 1 :5 to about 5:1 , about 1 :4 to about 4:1 , about 1 :3 to about 3:1 , about 1 :2 to about 2:1 , or about 1 :1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from about 1 :4 to about 6:1 , about 1 :1 to about 6:1 , about 2:1 to about 6:1 , about 3:1 to about 6:1 , or about 4:1 to about 6:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from about 1 :4 to about 5:1 , about 1 :1 to about 5:1 , about 2:1 to about 5:1 , about 3:1 to about 5:1 , or about 4:1 to about 5:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from about 1 :1 to about 4:1 , about 2:1 to about 4:1 , or about 3:1 to about 4:1 by volume.

[0101] In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :6 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :5 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :4 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :3 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :2 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 1 :1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 2:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 3:1 by volume. In some embodiments,the ratio of the first slurry solvent to the second slurry solvent is about 4:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 5:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 6:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is about 4:1 by volume, such as about 12:3 by volume.

[0102] In some embodiments, the slurry solvent system comprises a first slurry solvent and a second slurry solvent in a ratio of from 1 :6 to 6:1 by volume (first slurry solvent:second slurry solvent). In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from 1 :5 to 5:1 , 1 :4 to 4:1 , 1 :3 to 3:1, 1 :2 to 2:1, or 1 :1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from 1 :4 to 6:1 , 1 :1 to 6:1 , 2:1 to 6:1 , 3:1 to 6:1 , or 4:1 to 6:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from 1 :4 to 5:1 , 1 :1 to 5:1 , 2:1 to 5:1 , 3:1 to 5:1 , or 4:1 to 5:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is from 1 :1 to 4:1 , 2:1 to 4:1 , or 3:1 to 4:1 by volume.

[0103] In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :6 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :5 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :4 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :3 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :2 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 1 :1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 2:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 3:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 4:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 5:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 6:1 by volume. In some embodiments, the ratio of the first slurry solvent to the second slurry solvent is 4:1 by volume, such as 12:3 by volume.

[0104] In some embodiments, the slurry solvent system comprises a polar solvent. In some embodiments, the slurry solvent system comprises one slurry solvent and the slurry solvent is a polar solvent. In some embodiments, the slurry solvent system comprises more than one slurry solvent and at least one slurry solvent is a polar solvent. In some embodiments, the slurry solvent system comprises more than one solvent and each slurry solvent is individually a polar solvent. In some embodiments, the slurry solvent system comprises a first slurry solvent and a second slurry solvent, and each of the first and second slurry solvents are polar solvents. In further embodiments, the slurry solvent system comprises a polar protic solvent, such as, for example, an alcohol or a polar aprotic solvent, such as, for example, a ketone. In still further embodiments, the slurry solvent system comprises at least one polar solvent selected from methanol, ethanol, isopropanol, tertbutanol, pentanol acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, and cyclopentanone.

[0105] In some embodiments, the slurry solvent system comprises acetone. In further embodiments, the slurry solvent system comprises one slurry solvent and the slurry solvent is acetone.

[0106] In some embodiments, the slurry solvent system comprises MEK. In further embodiments, the slurry solvent system comprises one slurry solvent and the slurry solvent is MEK. In some embodiments, the slurry solvent system further comprises MIBK. In further embodiments, the slurry solvent system comprises a first slurry solvent and a second slurry solvent, where the first slurry solvent is MEK and the second slurry solvent is MIBK.

[0107] In some embodiments, the slurry solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK). In some embodiments, the ratio of MEK to MIBK is from about 1 :5 to about 5:1 , about 1 :4 to about 4:1 , about 1 :3 to about 3:1 , about 1 :2 to about 2:1 , or about 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is from about 1 :4 to about 6:1 , about 1 :1 to about 6:1 , about 2:1 to about 6:1 , about 3:1 to about 6:1 , or about 4:1 to about 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is from about 1 :4 to about 5:1 , about 1 :1 to about 5:1 , about 2:1 to about 5:1, about 3:1 to about 5:1 , or about 4:1 to about 5:1 by volume. In someembodiments, the ratio of MEK to MIBK is from about 1 :1 to about 4:1 , about 2:1 to about 4:1 , or about 3:1 to about 4:1 by volume.

[0108] In some embodiments, the ratio of MEK to MIBK is about 1 :6 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :5 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :4 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :3 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :2 by volume. In some embodiments, the ratio of MEK to MIBK is about 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is about 2:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 3:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 4:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is about 4:1 by volume, such as about 12:3 by volume.

[0109] In some embodiments, the slurry solvent system comprises MEK and MIBK in a ratio of from 1 :6 to 6:1 by volume (MEK:MIBK). In some embodiments, the ratio of MEK to MIBK is from 1 :5 to 5:1, 1 :4 to 4:1, 1 :3 to 3:1 , 1 :2 to 2:1 , or 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :4 to 6:1 , 1 :1 to 6:1 , 2:1 to 6:1 , 3:1 to 6:1 , or 4:1 to 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :4 to 5:1 , 1 :1 to 5:1 , 2:1 to 5:1 , 3:1 to 5:1 , or 4:1 to 5:1 by volume. In some embodiments, the ratio of MEK to MIBK is from 1 :1 to 4:1 , 2:1 to 4:1 , or 3:1 to 4:1 by volume.

[0110] In some embodiments, the ratio of MEK to MIBK is 1 :6 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :5 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :4 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :3 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :2 by volume. In some embodiments, the ratio of MEK to MIBK is 1 :1 by volume. In some embodiments, the ratio of MEK to MIBK is 2:1 by volume. In some embodiments, the ratio of MEK to MIBK is 3:1 by volume. In some embodiments, the ratio of MEK to MIBK is 4:1 by volume. In some embodiments, the ratio of MEK to MIBK is 5:1 by volume. In some embodiments, the ratioof MEK to MIBK is 6:1 by volume. In some embodiments, the ratio of MEK to MIBK is 4:1 by volume, such as 12:3 by volume.

[0111] In some instances, an improvement in chiral purity of the N-protected (-)-cytisine may be achieved by mixing the slurry at ambient conditions. However, in other instances, an elevated temperature may be required during mixing to facilitate purification of the N-protected (-)-cytisine. Thus, in some embodiments, the N-protected (-)-cytisine slurry is mixed about 30 °C to about 30 °C to about 95 °C. For example, the slurry may be stirred at a temperature of about 40 °C to about 95 °C, about 50 °C to about 90 °C, about 60 °C to about 85 °C, or about 70 °C to about 80 °C. In some embodiments, the combination is stirred at a temperature of about 50 °C to about 95 °C, about 60 °C to about 95 °C, about 70 °C to about 95 °C, about 80 °C to about 95 °C, about 60 °C to about 90 °C, about 70 °C to about 90 °C, about 80 °C to about 90 °C, about 65 °C to about 85 °C, about 70 °C to about 85 °C, about 75 °C to about 85 °C, or about 80 °C to about 85 °C. Alternatively, in some embodiments, the slurry is stirred at a temperature of about 30 °C to about 60 °C, about 30 °C to about 50 °C, about 30 °C to about 40 °C, about 40 °C to about 70 °C, about 40 °C to about 60 °C, about 40 °C to about 50 °C, about 50 °C to about 70 °C, or about 50 °C to about 60 °C. In some embodiments, the slurry is stirred at a temperature of about 30 °C, about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, about 85 °C, about 90 °C, or about 95 °C. In some embodiments, the slurry is stirred at a temperature of about 85 °C.

[0112] In some embodiments, the slurry is mixed at a temperature of 30 °C to 95 °C. For example, the slurry may be stirred at a temperature of 40 °C to 95 °C, 50 °C to 90 °C, 60 °C to 85 °C, or 70 °C to 80 °C. In some embodiments, the combination is stirred at a temperature of 50 °C to 95 °C, 60 °C to 95 °C, 70 °C to 95 °C, 80 °C to 95 °C, 60 °C to 90 °C, 70 °C to 90 °C, 80 °C to 90 °C, 65 °C to 85 °C, 70 °C to 85 °C, 75 °C to 85 °C, or 80 °C to 85 °C. Alternatively, in some embodiments, the slurry is mixed at a temperature of 30 °C to 60 °C, 30 °C to 50 °C, 30 °C to 40 °C, 40 °C to 70 °C, 40 °C to 60 °C, 40 °C to 50 °C, 50 °C to 70 °C, or 50 °C to 60 °C. In particular embodiments, the combination is stirred at a temperature of 30 °C, 35 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C,75 °C, 80 °C, 85 °C, 90 °C, or 95 °C. In some embodiments, the slurry is stirred at a temperature of 85 °C.

[0113] At the elevated temperature, the N-protected (-)-cytisine slurry may change form. For example, the N-protected (-)-cytisine may dissolve in the slurry solvent at the elevated temperature, thereby transforming from a slurry or suspension to a solution. Such transformation may facilitate purification of the N-protected (-)-cytisine; however, dissolution of the N-protected (-)-cytisine is not required to achieve purification.

[0114] The N-protected (-)-cytisine slurry may be mixed, at ambient or elevated temperatures, overnight, such as for about 10 minutes to about 18 hours. In some embodiments, the slurry is stirred at elevated temperature for about 10 minutes to about 6 hours, about 10 minutes to about 4 hours, about 10 minutes to about 2 hours, about 10 minutes to about 1 hour, about 30 minutes to about 6 hours, about 30 minutes to about 4 hours, about 30 minutes to about 2 hours, or about 30 minutes to about 1 hour. In some embodiments, the slurry is stirred at elevated temperature for about 1 hour to about 6 hours, about 1 hour to about 4 hours, about 1 hour to about 2 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, or about 4 hours to about 6 hours. In some embodiments, the slurry is stirred at elevated temperature for about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, or about 6 hours. In some embodiments, the slurry is stirred at elevated temperature for about 30 minutes.

[0115] In some embodiments, the slurry is mixed for about 6 hours to about 16 hours, about 6 hours to about 14 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 8 hours to about 18 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 8 hours to about 12 hours, or about 8 hours to about 10 hours, about 10 hours to about 18 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 18 hours, about 12 hours to about 16 hours, or about 12 hours to about 14 hours.

[0116] In some embodiments, the slurry is mixed for 10 minutes to 18 hours. In some embodiments, the slurry is stirred at elevated temperature for 10 minutes to 6 hours, 10 minutes to 4 hours, 10 minutes to 2 hours, 10 minutes to 1 hour, 30 minutes to 6 hours, 30 minutes to 4 hours, 30 minutes to 2 hours, or 30 minutes to 1 hour. In some embodiments, the slurry is stirred at elevated temperature for 1 hour to 6 hours, 1 hour to 4 hours, 1 hour to 2 hours, 2 hours to 6 hours, 2 hours to 4 hours, or 4 hours to 6 hours. In some embodiments, the slurry is stirred at elevated temperature for 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, or 6 hours. In some embodiments, the slurry is stirred at elevated temperature for 30 minutes. In some embodiments, the slurry is mixed for 6 hours to 16 hours, 6 hours to 14 hours, 6 hours to 12 hours, 6 hours to 10 hours, 8 hours to 18 hours, 8 hours to 16 hours, 8 hours to 14 hours, 8 hours to 12 hours, or 8 hours to 10 hours, 10 hours to 18 hours, 10 hours to 16 hours, 10 hours to 14 hours, 10 hours to 12 hours, 12 hours to 18 hours, 12 hours to 16 hours, or 12 hours to 14 hours.

[0117] After the slurry is mixed for a sufficient period of time, a seed crystal may be added to the slurry in an amount of about 0.1 mol% to about 5 mol%. In some embodiments, the seed crystal is added to the slurry in an amount of about 0.1 mol% to about 3 mol%, about 0.5 mol% to about 5 mol%, about 0.5 mol% to about 3 mol%, about 0.1 mol% to about 1 mol%, or about 0.5 mol% to about 1 mol%.

[0118] In some embodiments, the seed crystal is added to the slurry in an amount of 0.1 mol% to 5 mol%. In some embodiments, the seed crystal is added to the slurry in an amount of 0.1 mol% to 3 mol%, 0.5 mol% to 5 mol%, 0.5 mol% to 3 mol%, 0.1 mol% to 1 mol%, or 0.5 mol% to 1 mol%.

[0119] In some embodiments, the seed crystal is a N-protected (-)-cytisine salt. In some embodiments, the seed crystal is N-protected (-)-cytisine diaryl tartrate. In some embodiments, the seed crystal is N-protected (-)-cytisine dibenzoyl tartrate. In some embodiments, the seed crystal is (1 R,5S)-N-benzylcytisine dibenzoyl tartrate.

[0120] In some embodiments, the seed crystal is a N-protected (+)-cytisine salt. In some embodiments, the seed crystal is N-protected (+)-cytisine diaryl tartrate. In some embodiments, the seed crystal is N-protected (+)-cytisine dibenzoyl tartrate. In some embodiments, the seed crystal is (1 S,5R)-N-benzylcytisine dibenzoyl tartrate.

[0121] In some embodiments, the slurry is cooled from the elevated temperature to an intermediate temperature before the seed crystal is added. For example, in some embodiments, the slurry is cooled to an intermediate temperature about 1 °C to about 20 °C, about 2 °C to about 15 °C, or about 5 °C to about 12 °C below the elevated temperature before the seed crystal is added. In some embodiments, the slurry is cooled to an intermediate temperature about 2 °C, about 5 °C, about 8 °C, about 10 °C, about 12 °C, or about 15 °C below the elevated temperature before the seed crystal is added.

[0122] In some embodiments, the slurry is cooled to an intermediate temperature 1 °C to 20 °C, 2 °C to 15 °C, or 5 °C to 12 °C below the elevated temperature before the seed crystal is added. In some embodiments, the slurry is cooled to an intermediate temperature 2 °C, 5 °C, 8 °C, 10 °C, 12 °C, or 15 °C below the elevated temperature before the seed crystal is added.

[0123] In some embodiments, the slurry is cooled to an intermediate temperature of about 25 °C to about 80 °C. For example, the slurry may be cooled to an intermediate temperature of about 30 °C to about 80 °C, about 40 °C to about 80 °C, about 50 °C to about 80 °C, about 60 °C to about 80 °C, or about 70 °C to about 80 °C. In some embodiments, the slurry is cooled to an intermediate temperature of about 25 °C to about 75 °C, about 30 °C to about 75 °C, about 40 °C to about 75 °C, about 50 °C to about 75 °C, about 60 °C to about 75 °C, or about 65 °C to about 75 °C. In some embodiments, the slurry is cooled to an intermediate temperature of about 25 °C, about 30 °C, about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, or about 80 °C. In some embodiments, the slurry is cooled to an intermediate temperature of about 75 °C prior to seeding.

[0124] In some embodiments, the slurry is cooled to an intermediate temperature of 25 °C to 80 °C. For example, the slurry may be cooled to an intermediate temperature of30 °C to 80 °C, 40 °C to 80 °C, 50 °C to 80 °C, 60 °C to 80 °C, or 70 °C to 80 °C. In some embodiments, the slurry is cooled to an intermediate temperature of 25 °C to 75 °C, 30 °C to 75 °C, 40 °C to 75 °C, 50 °C to 75 °C, 60 °C to 75 °C, or 65 °C to 75 °C. In some embodiments, the slurry is cooled to an intermediate temperature of 25 °C, 30 °C, 35 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C, 75 °C, or 80 °C. In some embodiments, the slurry is cooled to an intermediate temperature of 75 °C prior to seeding.

[0125] In some embodiments, the elevated temperature is about 85 °C and the slurry is cooled to about 75 °C prior to seeding. In some embodiments, the elevated temperature is 85 °C and the slurry is cooled to 75 °C prior to seeding.

[0126] In some embodiments, after seeding, or, if no seed crystal is added to the slurry, after mixing is complete, the slurry is cooled to a low temperature, such as a temperature of about -10 °C to about 35 °C, about -5 °C to about 30 °C, or about 0 °C to about 25 °C. In some embodiments, the slurry is cooled to a temperature of about -5 °C, about -2 °C, about 0 °C, about 2 °C, about 5 °C, about 7 °C, about 10 °C, about 15 °C, about 20 °C, or about 25 °C. In some embodiments, the slurry is cooled to a temperature of about 0 °C.

[0127] In some embodiments, the slurry is cooled to a temperature of -10 °C to 35 °C, -5 °C to 30 °C, or 0 °C to 25 °C. In some embodiments, the slurry is cooled to a temperature of -5 °C, -2 °C, 0 °C, 2 °C, 5 °C, 7 °C, 10 °C, 15 °C, 20 °C, or 25 °C. In some embodiments, the slurry is cooled to a temperature of 0 °C.

[0128] In some embodiments, the slurry is cooled at a rate of about 0.1 °C / min to about 2 °C / min, from about 0.1 °C / min to about 1.5 °C / min, from about 0.1 °C / min to about 1 °C / min, or from about 0.1 °C / min to about 0.5 °C / min. In some embodiments, the slurry is cooled at a rate of about 0.1 °C / min, about 0.2 °C / min, about 0.3 °C / min, about 0.4 °C / min, about 0.5 °C / min, about 0.6 °C / min, about 0.7 °C / min, or about 0.8 °C / min. In some embodiments, the slurry is cooled at a rate of about 0.3 °C / min.

[0129] Finally, once the slurry has been sufficiently mixed, an enantiomerically enriched N-protected (-)-cytisine may be isolated from the slurry. When all or part of the N-protected (-)-cytisine dissolves in the slurry solvent during mixing, isolation may include precipitating the enantiomerically enriched N-protected (-)-cytisine from the slurry solvent.Once the enantiomerically enriched N-protected (-)-cytisine is suspended in the slurry solvent, isolation may be carried out by filtering the enantiomerically enriched N-protected (-)-cytisine away from the slurry solvent, decanting the slurry solvent off, or by any other suitable separation method known in the art. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is dried to remove residual solvent, such as according to the drying methods and conditions described with reference to initial isolation of the chiral N-protected (-)-cytisine. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in a salt form. In other embodiments, the enantiomerically enriched N-protected (-)-cytisine is in a freebase form. The form of the enantiomerically enriched N-protected (-)-cytisine will be the same form as the N-protected (-)-cytisine subjected to the optional purifying step 160.

[0130] Accordingly, after purifying the enantiomerically enriched N-protected (-)-cytisine may be an N-protected (-)-cytisine salt or a freebase N-protected (-)-cytisine. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is an N-protected (-)-cytisine salt. In further embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate, N-protected (-)-cytisine dibenzoyl-D-tartrate, N-protected (-)-cytisine di-p-toluoyl-L-tartrate, or N-protected (-)-cytisine di-p-toluoyl-D-tartrate. In still further embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate or N-protected (-)-cytisine dibenzoyl-D-tartrate.

[0131] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is selected from NBn-(-)-cytisine salt, NAc-(-)-cytisine salt, NBoc-(-)-cytisine salt, NFmoc-(-)-cytisine salt, and NCbz-(-)-cytisine salt. In further embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is NBn-(-)-cytisine salt or NBoc-(-)-cytisine salt. In still further embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is selected from NBn-(-)-cytisine dibenzoyl-L-tartrate, NBn-(-)-cytisine di-p-toluoyl-L-tartrate, NBn-(+)-cytisine dibenzoyl-D-tartrate, NBn-(+)-cytisine di-p-toluoyl-D-tartrate, NBoc-(-)-cytisine dibenzoyl-L-tartrate, NBoc-(-)-cytisine di-p-toluoyl-L-tartrate, NBoc-(+)-cytisine dibenzoyl-D-tartrate, NBoc-(+)-cytisine di-p-toluoyl-D-tartrate. In yetfurther embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is NBn-(-)-cytisine dibenzoyl-L-tartrate or NBn-(+)-cytisine dibenzoyl-D-tartrate. In other further embodiments, the enantiomerically enriched N-protected (-)-cytisine salt is NBoc-(-)-cytisine dibenzoyl-L-tartrate or NBoc-(+)-cytisine dibenzoyl-D-tartrate.

[0132] Alternatively, in some embodiments, the enantiomerically enriched N-protected (-)-cytisine is freebase N-protected (-)-cytisine. In further embodiments, the enantiomerically enriched N-protected (-)-cytisine is selected from NBn-(-)-cytisine, NAc-(-)-cytisine, NBoc-(-)-cytisine, NFmoc-(-)-cytisine, and NCbz-(-)-cytisine. In still further embodiments, the enantiomerically enriched N-protected (-)-cytisine is NBn-(-)-cytisine or NBoc-(-)-cytisine. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is NBn-(-)-cytisine. In other embodiments, the enantiomerically enriched N-protected (-)-cytisine is NBoc-(-)-cytisine.

[0133] The enantiomerically enriched N-protected (-)-cytisine, in salt or freebase form, may have a higher enantiomeric excess (ee) than the N-protected (-)-cytisine before it was subjected to the purifying step 160. For example, the enantiomerically enriched N-protected (-)-cytisine may have an ee of at least about 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine has an ee of about 97% to about 100%, about 97% to about 99.9%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98.5%, about 97% to about 98%, about 97.5% to about 99.9%, about 97.5% to about 99.9%, about 97.5% to about 99%, about 97.5% to about 98.5%, about 98% to about 99.9%, about 98% to about 99.5% or about 98% to about 99%. In some embodiments, the N-protected (-)-cytisine has an ee of about 97%, about 97.1%, about 97.3%, about 97.5%, about 97.7%, about 97.9%, about 98%, about 98.1%, about 98.3%, about 98.5%, about 98.7%, about 98.9%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9%.

[0134] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in freebase form and has an ee of at least about 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in freebase form and has an ee of about 97% to about 100%, about 97% to about 99.9%, about 97% to about 99.5%, about 97% toabout 99%, about 97% to about 98.5%, about 97% to about 98%, about 97.5% to about 99.9%, about 97.5% to about 99.9%, about 97.5% to about 99%, about 97.5% to about 98.5%, about 98% to about 99.9%, about 98% to about 99.5% or about 98% to about 99%. In some embodiments, the N-protected (-)-cytisine is in freebase form and has an ee of about 97%, about 97.1%, about 97.3%, about 97.5%, about 97.7%, about 97.9%, about 98%, about 98.1%, about 98.3%, about 98.5%, about 98.7%, about 98.9%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9%.

[0135] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in salt form and has an ee of at least about 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in salt form and has an ee of about 97% to about 100%, about 97% to about 99.9%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98.5%, about 97% to about 98%, about 97.5% to about 99.9%, about 97.5% to about 99.9%, about 97.5% to about 99%, about 97.5% to about 98.5%, about 98% to about 99.9%, about 98% to about 99.5% or about 98% to about 99%. In some embodiments, the N-protected (-)-cytisine is in salt form and has an ee of about 97%, about 97.1%, about 97.3%, about 97.5%, about 97.7%, about 97.9%, about 98%, about 98.1%, about 98.3%, about 98.5%, about 98.7%, about 98.9%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9%.

[0136] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine has an ee of at least 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine has an ee of about 97% to 100%, 97% to 99.9%, 97% to 99.5%, 97% to 99%, 97% to 98.5%, 97% to 98%, 97.5% to 99.9%, 97.5% to 99.9%, 97.5% to 99%, 97.5% to 98.5%, 98% to 99.9%, 98% to 99.5% or 98% to 99%. In some embodiments, the N-protected (-)-cytisine has an ee of 97%, 97.1%, 97.3%, 97.5%, 97.7%, 97.9%, 98%, 98.1%, 98.3%, 98.5%, 98.7%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%.

[0137] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in freebase form and has an ee of at least 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in freebase form and has an ee of about 97% to 100%, 97% to 99.9%, 97% to 99.5%, 97% to 99%, 97% to 98.5%, 97% to 98%, 97.5% to 99.9%, 97.5% to 99.9%, 97.5% to 99%, 97.5% to 98.5%, 98% to 99.9%, 98% to 99.5% or 98% to 99%. In some embodiments, the N-protected (-)-cytisine is in freebase form and has an ee of 97%, 97.1%, 97.3%, 97.5%, 97.7%, 97.9%, 98%, 98.1%, 98.3%, 98.5%, 98.7%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%.

[0138] In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in salt form and has an ee of at least 97%. In some embodiments, the enantiomerically enriched N-protected (-)-cytisine is in salt form and has an ee of about 97% to 100%, 97% to 99.9%, 97% to 99.5%, 97% to 99%, 97% to 98.5%, 97% to 98%, 97.5% to 99.9%, 97.5% to 99.9%, 97.5% to 99%, 97.5% to 98.5%, 98% to 99.9%, 98% to 99.5% or 98% to 99%. In some embodiments, the N-protected (-)-cytisine is in salt form and has an ee of 97%, 97.1%, 97.3%, 97.5%, 97.7%, 97.9%, 98%, 98.1%, 98.3%, 98.5%, 98.7%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%.

[0139] The referenced patents, patent applications, and scientific literature referred to herein are hereby incorporated by reference in their entirety as if each individual publication, patent, or patent application were specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

[0140] As can be appreciated from the disclosure above, the present technology has a wide variety of applications. The present technology is further illustrated by the following examples, which are only illustrative and are not intended to limit the definition and scope of the present technology in any way.EXAMPLESExample 1. Resolution of NBn-(rac)-Cvtisine

[0141] Resolution of NBn-(rac)-cytisine was attempted using a range of chiral acids in a range of different solvents according to the following procedure. Purified N-Bn-(rac)-cytisine (17 mg, 1 equivalent; er = 50.1 :49.9, %ee = 0.2) was combined with 1.2 equivalents of the chiral salt in 0.36 mL of the solvent. After stirring at 30 °C for a period of time, the reactions were assessed for solid formation and chiral resolution by chiral liquid chromatography (LC) and x-ray diffraction (XRD). Results of the chiral salt screen are shown in Table 1.Table 1. Chiral Salt Screen ResultsL()Tiidtararc ac+--S ()()110+--- Chlfiamporsoncuid acHeptane Oil Oil S ()()dlimanec+ O-- il Oil Oil Oil Oil Oil id acAcetonitrile Oil - - - - - - - EtO - - - ()DillDtpoouy+----- - - - Solid withH - iid ttararc ac ResolutionIPA Solid3- - - - - - - Acetone Solid3- - S (R)()13---, - - Solid with Solid - Chiidamporc ac Resolution Toluene Solid3Oil Oil Oil - - Oil Oilb- Solid with L()Liidtacc ac+-- - Solid with CPME Solid3Oil Solid - Resolution3Resolution2-MeTHF Solid3Oil - - - - - - DiblDenozy-- Solidiid with MIBK Solid3Oil - - - - ttararc ac Oil Resolution Solid with MTBE Solid3Oil - Solid3- - Oil Resolution Ethyl D()Mliidac ac+-- Solid3Oil - - - - - Oil AcetateO - - - - - Solid with Pentanol il -ResolutionaPoor solid form coating the vial in which the reaction was conductedbCPME = cyclopentyl methyl ether

[0142] The enantiomeric ratio (er) and enantiomeric excess (ee) of solids that exhibited resolution in the chiral salt screen are shown in Table 2.Table 2. Enantiomeric Excess from Chiral Salt Screen(+)-Di-p-toluoyl-D-tartaric acid Dibenzoyl-D-tartaric acid Enantiomeric %Enantiomeric Enantiomeric %Enantiomeric Ratio Excess Ratio Excess EtOH - - 89.0:11.0 78.0 Acetone - - 95.7:4.3 91.4 CPME 87.7:12.3 75.3 89.7:10.3 79.4 MIBK - - 91.2:8.8 82.4 MTBE - 75.0:25.0 50.0 Pentanol - - 87.15:12.85 74.3

[0143] As can be seen, (+)-dibenzoyl-D-tartaric acid in various solvents achieved at least some amount of resolution, though, acetone produced the best results with 91.4% ee.Example 2. Scale-up of NBn-(rac)-Cvtisine Resolution(+)-Dibenzoyl-D-tartaric acid

[0144] The resolution of NBn-(rac)-cytisine with (+)-dibenzoyl-D-tartaric acid was scaled-up according to the following process to assess resolution at large scale. First, N-Bn (rac)-cytisine (548 mg, 1 equivalent) was added to acetone (15 vols, 8.5 mL) to give a clear suspension, followed by addition of 1.07 equivalents of dibenzoyl-D-tartaric acid (750 mg) to give a clear solution. The reaction was mixed at ambient conditions overnight, though precipitation started after 5 minutes. After mixing overnight, the precipitated salt was washed with acetone (2 x 2 vols) and subsequently dried to give (1S,5R)-NBn-cytisine as a white solid (550 mg, 45% yield (90% recovery of single enantiomer), 94.1% ee by chiral LC.(-)-Dibenzoyl-L-tartaric acid

[0145] Additionally, the resolution of NBn-(rac)-cytisine with (-)-dibenzoyl-L-tartaric acid was scaled-up according to the following process to assess resolution at large scale. First, N-protected (rac)-cytisine (300 mg, 1 equivalent) was combined with 1.02 equivalents of dibenzoyl-L-tartaric acid (390 mg) in acetone (20 vols, 6 ml_). The reaction was then mixed at 50 °C and precipitation started after 20 minutes. The mixture was then cycled between 60 °C and 20 °C four times. After mixing and temperature cycling, the precipitated salt was washed with acetone (2 x 2 vols) and dried to give (1 R,5S)-NBn-cytisine as a white solid (228.5 mg, 33% yield (66% recovery of single enantiomer), 95.9% ee by chiral LC.Example 3. Resolution of NBoc-(rac)-Cvtisine

[0146] Resolution of NBoc-(rac)-cytisine with (-)-di-p-toluoyl-L-tartaric acid was tested in 2-methyl-tetrahydrofuran (2-MeTHF) and ethyl acetate (EtOAc) according to the following procedures.Resolution in 2-MeTHF

[0147] 200 mg of NBoc-(rac)-cytisine (1 equivalent) was dissolved in 2-MeTHF (12.5 rel. vol.) at 70 °C. Then, 1.0 equivalent of (-)-di-p-toluoyl-L-tartaric acid was added and the solution was stirred. After stirring, the solution was filtered to remove inorganic contaminants and then cooed to 60 °C. NBoc-(-)-cytisine di-p-toluoyl tartrate seeds (10% w / w) were added, the solution was cooled to 35 °C at a rate of 0.02 °C / min, and a sample was taken and assessed for %ee (31% ee). Then, two heat cool cycles were performed between 65 °C and 20 °C, after which a sample was taken and assessed for %ee (26% ee). Precipitate was redissolved in at 70 °C, cooled to 20 °C at a rate of 0.02 °C / min, left to stand at ambient conditions for 24 hours, and then dried under vacuum to provide a white solid (28 mg, 6% uncorrected yield, 24,5% ee).Resolution in EtOAc

[0148] 100 mg of NBoc-(rac)-cytisine (1 equivalent) was dissolved in EtOAc (20 rel. vol.) at 70 °C and then filtered to remove inorganic contaminants. After filtering, 1.0 equivalent (Sample A) or 0.5 equivalent (Sample B) of (-)-di-p-toluoyl-L-tartaric acid wasadded and the solution was stirred. The solution was cooled to 60 °C, and NBoc-(-)-cytisine di-p-toluoyl tartrate seeds (10% w / w) were added. The solution was subsequently cooled to 20 °C at a rate of 0.05 °C / min, filtered and washed with EtOAc (1 x 10 rel. vol.), and then dried under vacuum to provide a white solid. The results are provided in Table 3.Table 3. Results from Resolution in EtOAcEnantiomericSample Weight (mg) Yield (%)Excess (% ee)A 36.64 10 51.9B 23.56 5.6 53.5Example 4. Chiral Purity Uplift of (1S,5R)-NBn-Cvtisine Dibenzoyl-D-tartrate Salt

[0149] A sample of (1 S,5R)-NBn-cytisinedibenzoyl-D-tartrate salt with an enantiomeric excess of 95.58% was prepared according to the process of the present technology. To improve chiral purity, the (1 S,5R)-NBn-cytisine dibenzoyl-D-tartrate salt was slurried (i.e., suspended and stirred) in acetone or methyl ethyl ketone (MEK) at 40 °C overnight. Slurrying in acetone gave 67% isolated yield with 98.56% ee and slurrying in MEK gave 74% isolated yield with 97.72% ee.

[0150] Based on the uplift in %ee achieved in the initial studies, the slurry was tested at larger scale. Specifically, 6.4 g of (1 S,5R)-NBn-cytisine dibenzoyl-D-tartrate salt was slurried in 5 vols of acetone at 40 °C overnight. The slurry solution was then cooled, filtered, washed with acetone (2 x 1 cake volume), and dried to give a white solid at 91% yield and 97.08% ee, as determined by chiral LG and differential scanning calorimetry (DSC).Example 5. Solubility of (1 R,5S)-NBn-Cvtisine Dibenzoyl-L-tartrate Salt

[0151] To improve the design of the resolution in the process, the solubility of (1 R,5S)-NBn-cytisine dibenzoyl-L-tartrate salt was studied in various solvents (MIBK, acetone, and MEK) using Crystall 6. The solubility results are shown in Table 4.Table 4. Solubility of (1 R,5S)-NBn-Cytisine Dibenzoyl-L-tartrate Salt in Different Solvents ConcentrationSolvent Temperature Relative Volume Solubility (mg / mL)MIBK 90 °C < 29 lowAcetone 55 °C 26 38 medium MEK 75 °C 42 24 medium

[0152] As can be seen, the (1 R,5S)-NBn-cytisine dibenzoyl-L-tartrate salt exhibited greater, but still limited, solubility in acetone and MEK than in MIBK. Accordingly, acetone and MEK may be suitable crystallization solvents, however, the limited solubility suggests that single solvent recrystallization is unlikely.Example 6. Large Scale Resolution and Recrystallization

[0153] The large scale applicability of the resolution and subsequent enantiomeric enrichment processes was assessed using 1.0 kilogram (kg) inputs of N-benzyl-(rac)-cytisine (NBn-(rac)-cytisine) and crude (1 R,5S)-N-benzylcytisine dibenzoyl-L-ditartrate salt ((1 R,5S)-NBn-cytisine dibenzoyl tartrate salt). Protocol details and results of the respective large scale processes follow.Initial Chiral Resolution and Salt Formation

[0154] NBn-(rac)-cytisine (1.00 kg) was dissolved in a mixture of methyl ethyl ketone (MEK; 12.00 L) and methylisobutyl ketone (MIBK; 3.00 L) at 15 to 25 °C with agitation. Dibenzoyl-L-tartaric acid (1.10 eq., 1.41 kg) was added to the resulting solution at 15 to 25 °C , and the mixture was then heated to 85 °C ± 2 °C and held at this temperature for approximately 30 minutes, then cooled to 75 °C ± 2 °C at a rate of 5 °C / min.

[0155] To initiate crystallization, seeds of (1 R,5S)-NBn-cytisine dibenzoyl-L-ditartrate salt (minimum 95% ee, 0.02 wt, 0.02 kg) were added once the solution reached 75 °C ± 2 °C and the mixture was stirred at this temperature for approximately 30 minutes. The mixture was then subjected to a temperature cycling procedure to promote selective crystallization of the desired enantiomer. Specifically, the mixture was cooled to 0 °C ± 2 °C overapproximately 6 hours and held at this temperature for about 30 minutes, then warmed to 65 °C ± 2 °C and held for 30 minutes. This cooling and warming cycle was repeated once more, after which the mixture was cooled to 0 °C ± 2 °C over not less than 6 hours and held at this temperature for not less than 1 hour to complete crystallization.

[0156] The product was isolated by vacuum filtration as an off-white solid and the filter cake was washed twice with a pre-mixed solution of MIBK (0.50 L, 0.50 L / kg) and MEK (2.00 L, 2.00 L / kg). The solid was dried under vacuum at 40 °C to give the crude (1 R,5S)-NBn-cytisine dibenzoyl-L-ditartrate salt.Recrystallization for Enantiomeric Enrichment

[0157] The crude (1 R,5S)-NBn-cytisine dibenzoyl-L-tartrate salt obtained above (1.00 kg) was dissolved in a mixture of MEK (24.00 L, 24.00 L / kg) and MIBK (6.00 L, 6.00 L / kg) at 15 to 25 °C with agitation. The mixture was heated to 85 °C ± 2 °C and held for approximately 30 minutes to ensure complete dissolution, then cooled to 75 °C ± 2 °C at a rate of 5 °C / min.

[0158] Seeds of (1 R,5S)-NBn-cytisine dibenzoyl-L-tartrate salt (minimum 99% ee, 0.02 wt, 0.02 kg) were added at 75 °C ± 2 °C and the mixture was stirred at this temperature for approximately 30 minutes. The mixture was then cooled to 0 °C ± 2 °C over not less than 6 hours and held at this temperature for approximately 18 hours to allow crystallization to reach completion.

[0159] The product was isolated by vacuum filtration as an off-white solid and the filter cake was washed twice with a pre-mixed solution of MIBK (0.50 L, 0.50 L / kg) and MEK (2.00 L, 2.00 L / kg). The solid was dried under vacuum at 40 °C to give (1 R,5S)-NBn-cytisine dibenzoyl tartrate salt as an off-white crystalline solid.Yield and Analytical Data

[0160] The uncorrected yield of NBn-(-)-cytisine dibenzoyl-L-tartrate salt after resolution and recrystallization was 0.68 kg (30%) based on a 1.00 kg corrected input of NBn-(rac)-cytisine, with an expected potency of greater than 96 wt% and a corrected yield of 0.66 kg (29%). The recrystallized product was obtained in greater than 99.0 LCAP (liquid chromatography-atmospheric pressure) chemical purity by UPLC (ultra performance liquidchromatography) and greater than 99% ee by chiral liquid chromatography (FIG. 2A). By contrast, the resolved, unrecrystallized product exhibited 97.8% ee (FIG. 2B), confirming that the enantiomeric enrichment step is applicable to large scale processes.

[0161] Various embodiments of the present technology are set forth herein below in paragraphs

[0162] -

[0248] :

[0162] Embodiment 1. A process for preparing N-protected (-)-cytisine from N-protected (rac)-cytisine, the process comprising resolving the N-protected (rac)-cytisine with a chiral diaryl-tartaric acid.

[0163] Embodiment 2. A compound prepared by resolving N-protected (rac)-cytisine with a chiral diaryl-tartaric acid, wherein the compound is N-protected (-)-cytisine.

[0164] Embodiment 3. The process or compound of embodiment 1 or 2, wherein resolving the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid comprises combining N-protected (rac)-cytisine with the chiral diaryl-tartaric acid in a solvent system.

[0165] Embodiment 4. A process for resolving N-protected (rac)-cytisine, comprising:combining N-protected (rac)-cytisine with a chiral diaryl-tartaric acid in a solvent system; andforming N-protected (-)-cytisine.

[0166] Embodiment 5. The process or compound of any one of embodiments 1-4, wherein the chiral diaryl-tartaric acid is dibenzoyl-L-tartaric acid, dibenzoyl-D-tartaric acid, (+)-di-p-toluoyl-D-tartaric acid, or (-)-di-p-toluoyl-L-tartaric acid.

[0167] Embodiment 6. The process or compound of any one of embodiments 1-5, wherein the N-protected (rac)-cytisine is selected from N-benzylcytisine, N-tert-butoxycarbonylcytisine, N-fluorenylmethoxycarbonylcytisine, N-acetylcytisine, and N-carboxybenzylcytisine.

[0168] Embodiment 7. The process or compound of any one of embodiments 1-6, wherein the N-protected (rac)-cytisine is N-benzylcytisine.

[0169] Embodiment 8. The process or compound of any one of embodiments 3-7, wherein the solvent system comprises a first solvent and a second solvent.

[0170] Embodiment 9. The process or compound of embodiment 8, wherein at least one of the first and second solvents is a polar solvent.

[0171] Embodiment 10. The process or compound of embodiment 8, wherein the first and second solvents are each independently a polar solvent.

[0172] Embodiment 11. The process of compound of embodiment 9 or 10, wherein the polar solvent is a ketone solvent or an alcohol solvent.

[0173] Embodiment 12. The process or compound of any one of embodiments 3-11 , wherein the solvent system comprises at least one polar solvent selected from the group consisting of ethanol, acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, cyclopentanone, methanol, isopropanol, tert-butanol, and pentanol.

[0174] Embodiment 13. The process or compound of embodiment 12, wherein the solvent system comprises MEK and MIBK.

[0175] Embodiment 14. The process or compound of embodiment 13, wherein the solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

[0176] Embodiment 15. The process or compound of embodiment 13 or 14, wherein the ratio of MEK to MIBK is about 4:1 by volume.

[0177] Embodiment 16. The process or compound of any one of embodiments 1-15, wherein, relative to 1 equivalent of the N-protected (rac)-cytisine, the chiral diaryl-tartaric acid is present in about 1.0 equivalents to about 2.0 equivalents.

[0178] Embodiment 17. The process or compound of any one of embodiments 1-16, wherein, relative to 1 equivalent of the N-protected (rac)-cytisine, the chiral diaryl-tartaric acid is present in about 1.2 molar equivalents.

[0179] Embodiment 18. The process or compound of any one of embodiments 1-15, wherein the chiral diaryl-tartaric acid is present in a molar ratio of about 1 :1 to about 2:1 of acid to N-protected (rac)-cytisine.

[0180] Embodiment 19. The process or compound of any one of embodiments 1-15 and 18, wherein the chiral diaryl-tartaric acid is present in a molar ratio of about 1.2:1 of acid to N-protected (rac)-cytisine.

[0181] Embodiment 20. The process or compound of any one of embodiments 3-19, wherein combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid in the solvent system comprises heating the combination to a temperature of about 30 °C to about 95 °C.

[0182] Embodiment 21. The process or compound of any one of embodiments 3-20, wherein the combination is heated to a temperature of about 80 °C to about 95 °C.

[0183] Embodiment 22. The process or compound of any one of embodiments 3-21 , wherein the combination is heated to a temperature of about 85 °C.

[0184] Embodiment 23. The process or compound of any one of embodiments 20-22, wherein the combination is heated to the elevated temperature for a period of about 10 minutes to about 6 hours.

[0185] Embodiment 24. The process or compound of any one of embodiments 20-23, wherein the combination is heated to the elevated temperature for a period of about 30 minutes to about 6 hours.

[0186] Embodiment 25. The process or compound of any one of embodiments 20-24, wherein the combination is heated to the elevated temperature for about 30 minutes.

[0187] Embodiment 26. The process or compound of any one of embodiments 20-25, wherein, after heating the combination to the elevated temperature, the combination is cooled to an intermediate temperature of about 25 °C to about 80 °C prior to adding a seed crystal.

[0188] Embodiment 27. The process or compound of embodiment 26, wherein the intermediate temperature is about 65 °C to about 80 °C.

[0189] Embodiment 28. The process or compound of embodiment 26 or 27, wherein the combination is heated to a temperature of about 85 °C and is cooled to a temperature of about 75 °C prior to adding the seed crystal.

[0190] Embodiment 29. The process or compound of any one of embodiments 26-28, wherein the seed crystal is added in an amount of about 0.5 mol% to about 3 mol%.

[0191] Embodiment 30. The process or compound of any one of embodiments 26-29, wherein, after adding the seed crystal, the combination is cooled to a temperature of about -10 °C to about 35 °C.

[0192] Embodiment 31. The process or compound of any one of embodiments 26-29, wherein, after adding the seed crystal, the combination is cooled to a temperature of about 0 °C.

[0193] Embodiment 32. The process or compound of embodiment 30 or 31, wherein the combination is cooled at a rate of about 0.1 °C / min to about 2 °C / min.

[0194] Embodiment 33. The process or compound of any one of embodiments 30-32, wherein the combination is cooled at a rate of about 0.3 °C / min.

[0195] Embodiment 34. The process or compound of any one of embodiments 26-29, further comprising, after adding the seed crystal, subjecting the combination to a ripening process comprising one or more heating and cooling cycles.

[0196] Embodiment 35. The process or compound of embodiment 34, wherein the ripening process comprises at least 2, at least 3, at least 4, or at least 5 heating and cooling cycles.

[0197] Embodiment 36. The process or compound of embodiment 34 or 35, wherein the ripening process comprises 2 heating and cooling cycles.

[0198] Embodiment 37. The process or compound of any one of embodiments 34-36, wherein each heating and cooling cycle comprises heating the combination to an elevatedtemperature of about 30 °C to about 95 °C and then cooling the combination to a low temperature of about -10 °C to about 35 °C.

[0199] Embodiment 38. The process or compound of any one of embodiments 34-37, wherein each heating and cooling cycle comprises heating the combination to an elevated temperature of about 65 °C and then cooling the combination to a low temperature of about 0 °C.

[0200] Embodiment 39. The process or compound of any one of embodiments 34-38, wherein, during each heating cycle, the combination is held at the elevated temperature for about 1 minute to about 60 minutes.

[0201] Embodiment 40. The process or compound of any one of embodiments 34-39, wherein, during each heating cycle, the combination is held at the elevated temperature for about 30 minutes.

[0202] Embodiment 41. The process or compound of any one of embodiments 34-40, wherein, during each cooling cycle, the combination is held at the low temperature for about 1 minute to about 120 minutes.

[0203] Embodiment 42. The process or compound of any one of embodiments 34-41 , wherein the combination is held at the low temperature for about 30 minutes between successive heating and cooling cycles.

[0204] Embodiment 43. The process or compound of any one of embodiments 34-42, wherein the combination is held at the low temperature for about 1 hour or more during a final cooling cycle.

[0205] Embodiment 44. The process or compound of any one of embodiments 3-43, wherein combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid comprises forming a chiral N-protected salt.

[0206] Embodiment 45. The process or compound of embodiment 44, wherein the chiral N-protected salt is a N-protected (-)-cytisine salt when the chiral diaryl-tartaric acid is dibenzoyl-L-tartaric acid or (-)-di-p-toluoyl-L-tartaric acid.

[0207] Embodiment 46. The process or compound of embodiment 44, wherein the chiral N-protected salt is a N-protected (+)-cytisine salt when the chiral diaryl-tartaric acid is dibenzoyl-D-tartaric acid or (+)-di-p-toluoyl-D-tartaric acid.

[0208] Embodiment 47. The process or compound of any one of embodiments 1-46, further comprising isolating the N-protected (-)-cytisine.

[0209] Embodiment 48. The process or compound of embodiment 47, wherein isolating the N-protected (-)-cytisine comprises, when combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid forms a N-protected (-)-cytisine salt:removing the N-protected (-)-cytisine salt from the solvent system.

[0210] Embodiment 49. The process or compound of any one of embodiments 1-48, wherein the N-protected (-)-cytisine salt has an enantiomeric excess (ee) of at least about 90%.

[0211] Embodiment 50. The process or compound of any one of embodiments 1-49, wherein the N-protected (-)-cytisine salt has an ee of about 90% to about 96%.

[0212] Embodiment 51. The process or compound of any one of embodiments 1-49, wherein the N-protected (-)-cytisine is a N-protected (-)-cytisine salt.

[0213] Embodiment 52. The process or compound of any one of embodiments 48-51 , wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate.

[0214] Embodiment 53. The process or compound of any one of embodiments 48-52, wherein the N-protected (-)-cytisine dibenzoyl-L-tartrate is N-benzyl-(-)-cytisine dibenzoyl-L-tartrate.

[0215] Embodiment 54. The process or compound of embodiment 48, further comprising transforming the N-protected (-)-cytisine salt to N-protected (-)-cytisine in a freebase form.

[0216] Embodiment 55. The process or compound of embodiment 47, wherein isolating the N-protected (-)-cytisine comprises, when combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid forms a N-protected (+)-cytisine salt:removing the N-protected (+)-cytisine salt from the solvent system; and crystallizing the N-protected (-)-cytisine from the solvent system.

[0217] Embodiment 56. The process or compound of any one of embodiments 1-55, wherein the N-protected (-)-cytisine has an enantiomeric excess (ee) of at least about 90%.

[0218] Embodiment 57. The process or compound of any one of embodiments 1-56, wherein the N-protected (-)-cytisine has an ee of about 90% to about 96%.

[0219] Embodiment 58. The process or compound of any one of embodiments 47-57, further comprising, after isolating the N-protected (-)-cytisine:suspending the N-protected (-)-cytisine in a slurry solvent system to provide an N-protected (-)-cytisine slurry;mixing the N-protected (-)-cytisine slurry; andisolating enantiomerically enriched N-protected (-)-cytisine from the slurry.

[0220] Embodiment 59. The process or compound of embodiment 58, wherein the N-protected (-)-cytisine is a N-protected (-)-cytisine salt.

[0221] Embodiment 60. The process or compound of embodiment 58 or 59, wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate.

[0222] Embodiment 61. The process or compound of any one of embodiments 58-60, wherein the N-protected (-)-cytisine dibenzoyl-L-tartrate is N-benzyl-(-)-cytisine dibenzoyl-L-tartrate.

[0223] Embodiment 62. The process or compound of embodiment 58, wherein the slurry solvent system comprises a first slurry solvent and a second slurry solvent.

[0224] Embodiment 63. The process or compound of embodiment 62, wherein at least one of the first and second slurry solvents is a polar solvent.

[0225] Embodiment 64. The process or compound of embodiment 62, wherein the first and second slurry solvents are each independently a polar solvent.

[0226] Embodiment 65. The process of compound of embodiment 63 or 64, wherein the polar solvent is a ketone solvent or an alcohol solvent.

[0227] Embodiment 66. The process or compound of any one of embodiments 58-65, wherein the slurry solvent system comprises at least one polar solvent selected from the group consisting of ethanol, acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, cyclopentanone, methanol, isopropanol, tert-butanol, and pentanol.

[0228] Embodiment 67. The process or compound of any one of embodiments 58-66, wherein the slurry solvent system comprises one solvent and the solvent is acetone or MEK.

[0229] Embodiment 68. The process or compound of embodiment 67, wherein the solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

[0230] Embodiment 69. The process or compound of embodiment 68, wherein the ratio of MEK to MIBK is about 4:1 by volume.

[0231] Embodiment 70. The process or compound of any one of embodiments 58-67, wherein the enantiomerically enriched N-protected (-)-cytisine has an enantiomeric excess (ee) of at least about 97%.

[0232] Embodiment 71. The process or compound of any one of embodiments 58-67, wherein the enantiomerically enriched N-protected (-)-cytisine is an enantiomerically enriched N-protected (-)-cytisine salt and has an enantiomeric excess (ee) of at least about 97%.

[0233] Embodiment 72. The process or compound of any one of embodiments 58-70, wherein the enantiomerically enriched N-protected (-)-cytisine has an ee of about 97% to about 99.9%.

[0234] Embodiment 73. The process or compound of any one of embodiments 58-72, wherein the wherein the enantiomerically enriched N-protected (-)-cytisine is an enantiomerically enriched N-protected (-)-cytisine salt and has an ee of about 97% to about 99.9%.

[0235] Embodiment 74. An N-protected (-)-cytisine salt that is N-protected (-)-cytisine dibenzoyl-L-tartrate.

[0236] Embodiment 75. A process for improving the enantiomeric purity of a N-protected (-)-cytisine salt, comprising:suspending the N-protected (-)-cytisine salt in a slurry solvent system to provide a N-protected (-)-cytisine salt slurry;mixing the N-protected (-)-cytisine salt slurry; andisolating an enantiomerically enriched N-protected (-)-cytisine salt from the slurry.

[0237] Embodiment 76. The process of embodiment 75, wherein the N-protected (-)-cytisine salt has an ee of about 90% to about 96%.

[0238] Embodiment 77. The process of embodiment 75 or 76, wherein the slurry solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

[0239] Embodiment 78. The process of embodiment 77, wherein the ratio of MEK to MIBK is about 4:1 by volume.

[0240] Embodiment 79. The process of any one of embodiments 75-78, wherein the enantiomerically enriched N-protected (-)-cytisine salt has an enantiomeric excess (ee) of at least about 97%.

[0241] Embodiment 80. The process of any one of embodiments 75-79, wherein the enantiomerically enriched N-protected (-)-cytisine salt has an ee of about 97% to about 99.9%.

[0242] Embodiment 81. The process of any one of embodiments 75-80, wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate or N-protected (-)-cytisine dibenzoyl-D-tartrate.

[0243] Embodiment 82. The process of embodiment 81, wherein the N-protected (-)-cytisine salt is (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate.

[0244] Embodiment 83. A process for preparing (1 R,5S)-N-benzylcytisine from N-benzyl-(rac)-cytisine, the process comprising resolving the N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

[0245] Embodiment 84. A (1 R,5S)-N-benzylcytisine salt prepared by resolving N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

[0246] Embodiment 85. The process or salt of embodiment 83 or 84, wherein resolving the N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid comprises combining N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid in a solvent system.

[0247] Embodiment 86. A process for resolving N-benzyl-(rac)-cytisine, comprising: combining N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid in a solvent system; andforming (1 R,5S)-N-benzylcytisine.

[0248] Embodiment 87. An (1 R,5S)-N-benzylcytisine salt that is (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate.

Claims

CLAIMSl / We claim:

1. A process for preparing N-protected (-)-cytisine from N-protected (rac)-cytisine, the process comprising resolving the N-protected (rac)-cytisine with a chiral diaryltartaric acid.

2. A compound prepared by resolving N-protected (rac)-cytisine with a chiral diaryl-tartaric acid, wherein the compound is N-protected (-)-cytisine.

3. The process or compound of claim 1 or 2, wherein resolving the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid comprises combining N-protected (rac)-cytisine with the chiral diaryl-tartaric acid in a solvent system.

4. A process for resolving N-protected (rac)-cytisine, comprising:combining N-protected (rac)-cytisine with a chiral diaryl-tartaric acid in a solvent system; andforming N-protected (-)-cytisine.

5. The process or compound of any one of claims 1 -4, wherein the chiral diaryltartaric acid is dibenzoyl-L-tartaric acid, dibenzoyl-D-tartaric acid, (+)-di-p-toluoyl-D-tartaric acid, or (-)-di-p-toluoyl-L-tartaric acid.

6. The process or compound of any one of claims 1 -5, wherein the N-protected (rac)-cytisine is selected from N-benzylcytisine, N-tert-butoxycarbonylcytisine, N-fluorenylmethoxycarbonylcytisine, N-acetylcytisine, and N-carboxybenzylcytisine.

7. The process or compound of any one of claims 1 -6, wherein the N-protected (rac)-cytisine is N-benzylcytisine.

8. The process or compound of any one of claims 3-7, wherein the solvent system comprises a first solvent and a second solvent.

9. The process or compound of claim 8, wherein at least one of the first and second solvents is a polar solvent.

10. The process or compound of claim 8, wherein the first and second solvents are each independently a polar solvent.

11. The process of compound of claim 9 or 10, wherein the polar solvent is a ketone solvent or an alcohol solvent.

12. The process or compound of any one of claims 3-11 , wherein the solvent system comprises at least one polar solvent selected from the group consisting of ethanol, acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, cyclopentanone, methanol, isopropanol, tert-butanol, and pentanol.

13. The process or compound of claim 12, wherein the solvent system comprises MEK and MIBK.

14. The process or compound of claim 13, wherein the solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

15. The process or compound of claim 13 or 14, wherein the ratio of MEK to MIBK is about 4:1 by volume.

16. The process or compound of any one of claims 1 -15, wherein, relative to 1 equivalent of the N-protected (rac)-cytisine, the chiral diaryl-tartaric acid is present in about 1.0 equivalents to about 2.0 equivalents.

17. The process or compound of any one of claims 1 -16, wherein, relative to 1 equivalent of the N-protected (rac)-cytisine, the chiral diaryl-tartaric acid is present in about 1.2 molar equivalents.

18. The process or compound of any one of claims 1 -15, wherein the chiral diaryl-tartaric acid is present in a molar ratio of about 1 :1 to about 2:1 of acid to N-protected (rac)-cytisine.

19. The process or compound of any one of claims 1 -15 and 18, wherein the chiral diaryl-tartaric acid is present in a molar ratio of about 1.2:1 of acid to N-protected (rac)-cytisine.

20. The process or compound of any one of claims 3-19, wherein combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid in the solvent system comprises heating the combination to a temperature of about 30 °C to about 95 °C.

21. The process or compound of any one of claims 3-20, wherein the combination is heated to a temperature of about 80 °C to about 95 °C.

22. The process or compound of any one of claims 3-21 , wherein the combination is heated to a temperature of about 85 °C.

23. The process or compound of any one of claims 20-22, wherein the combination is heated to the elevated temperature for a period of about 10 minutes to about 6 hours.

24. The process or compound of any one of claims 20-23, wherein the combination is heated to the elevated temperature for a period of about 30 minutes to about 6 hours.

25. The process or compound of any one of claims 20-24, wherein the combination is heated to the elevated temperature for about 30 minutes.

26. The process or compound of any one of claims 20-25, wherein, after heating the combination to the elevated temperature, the combination is cooled to an intermediate temperature of about 25 °C to about 80 °C prior to adding a seed crystal.

27. The process or compound of claim 26, wherein the intermediate temperature is about 65 °C to about 80 °C.

28. The process or compound of claim 26 or 27, wherein the combination is heated to a temperature of about 85 °C and is cooled to a temperature of about 75 °C prior to adding the seed crystal.

29. The process or compound of any one of claims 26-28, wherein the seed crystal is added in an amount of about 0.5 mol% to about 3 mol%.

30. The process or compound of any one of claims 26-29, wherein, after adding the seed crystal, the combination is cooled to a temperature of about -10 °C to about 35 °C.

31. The process or compound of any one of claims 26-29, wherein, after adding the seed crystal, the combination is cooled to a temperature of about 0 °C.

32. The process or compound of claim 30 or 31 , wherein the combination is cooled at a rate of about 0.1 °C / min to about 2 °C / min.

33. The process or compound of any one of claims 30-32, wherein the combination is cooled at a rate of about 0.3 °C / min.

34. The process or compound of any one of claims 26-29, further comprising, after adding the seed crystal, subjecting the combination to a ripening process comprising one or more heating and cooling cycles.

35. The process or compound of claim 34, wherein the ripening process comprises at least 2, at least 3, at least 4, or at least 5 heating and cooling cycles.

36. The process or compound of claim 34 or 35, wherein the ripening process comprises 2 heating and cooling cycles.

37. The process or compound of any one of claims 34-36, wherein each heating and cooling cycle comprises heating the combination to an elevated temperature of about 30 °C to about 95 °C and then cooling the combination to a low temperature of about -10 °C to about 35 °C.

38. The process or compound of any one of claims 34-37, wherein each heating and cooling cycle comprises heating the combination to an elevated temperature of about 65 °C and then cooling the combination to a low temperature of about 0 °C.

39. The process or compound of any one of claims 34-38, wherein, during each heating cycle, the combination is held at the elevated temperature for about 1 minute to about 60 minutes.

40. The process or compound of any one of claims 34-39, wherein, during each heating cycle, the combination is held at the elevated temperature for about 30 minutes.

41. The process or compound of any one of claims 34-40, wherein, during each cooling cycle, the combination is held at the low temperature for about 1 minute to about 120 minutes.

42. The process or compound of any one of claims 34-41 , wherein the combination is held at the low temperature for about 30 minutes between successive heating and cooling cycles.

43. The process or compound of any one of claims 34-42, wherein the combination is held at the low temperature for about 1 hours or more during a final cooling cycle.

44. The process or compound of any one of claims 3-43, wherein combining the N-protected (rac)-cytisine with the chiral diaryl-tartaric acid comprises forming a chiral N-protected salt.

45. The process or compound of claim 44, wherein the chiral N-protected salt is a N-protected (-)-cytisine salt when the chiral diaryl-tartaric acid is dibenzoyl-L-tartaric acid or (-)-di-p-toluoyl-L-tartaric acid.

46. The process or compound of claim 44, wherein the chiral N-protected salt is a N-protected (+)-cytisine salt when the chiral diaryl-tartaric acid is dibenzoyl-D-tartaric acid or (+)-di-p-toluoyl-D-tartaric acid.

47. The process or compound of any one of claims 1 -46, further comprising isolating the N-protected (-)-cytisine.

48. The process or compound of claim 47, wherein isolating the N-protected (-)-cytisine comprises, when combining the N-protected (rac)-cytisine with the chiral diaryltartaric acid forms a N-protected (-)-cytisine salt:removing the N-protected (-)-cytisine salt from the solvent system.

49. The process or compound of any one of claims 1 -48, wherein the N-protected (-)-cytisine salt has an enantiomeric excess (ee) of at least about 90%.

50. The process or compound of any one of claims 1 -49, wherein the N-protected (-)-cytisine salt has an ee of about 90% to about 96%.

51. The process or compound of any one of claims 1 -49, wherein the N-protected (-)-cytisine is a N-protected (-)-cytisine salt.

52. The process or compound of any one of claims 48-51 , wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate.

53. The process or compound of any one of claims 48-52, wherein the N-protected (-)-cytisine dibenzoyl-Z_-tartrate is N-benzyl-(-)-cytisine dibenzoyl-L-tartrate.

54. The process or compound of claim 48, further comprising transforming the N-protected (-)-cytisine salt to N-protected (-)-cytisine in a freebase form.

55. The process or compound of claim 47, wherein isolating the N-protected (-)-cytisine comprises, when combining the N-protected (rac)-cytisine with the chiral diaryltartaric acid forms a N-protected (+)-cytisine salt:removing the N-protected (+)-cytisine salt from the solvent system; and crystallizing the N-protected (-)-cytisine from the solvent system.

56. The process or compound of any one of claims 1 -55, wherein the N-protected (-)-cytisine has an enantiomeric excess (ee) of at least about 90%.

57. The process or compound of any one of claims 1 -56, wherein the N-protected (-)-cytisine has an ee of about 90% to about 96%.

58. The process or compound of any one of claims 47-57, further comprising, after isolating the N-protected (-)-cytisine:suspending the N-protected (-)-cytisine in a slurry solvent system to provide an N-protected (-)-cytisine slurry;mixing the N-protected (-)-cytisine slurry; andisolating enantiomerically enriched N-protected (-)-cytisine from the slurry.

59. The process or compound of claim 58, wherein the N-protected (-)-cytisine is a N-protected (-)-cytisine salt.

60. The process or compound of claim 58 or 59, wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate.

61. The process or compound of any one of claims 58-60, wherein the N-protected (-)-cytisine dibenzoyl-L-tartrate is N-benzyl-(-)-cytisine dibenzoyl-L-tartrate.

62. The process or compound of claim 58, wherein the slurry solvent system comprises a first slurry solvent and a second slurry solvent.

63. The process or compound of claim 62, wherein at least one of the first and second slurry solvents is a polar solvent.

64. The process or compound of claim 62, wherein the first and second slurry solvents are each independently a polar solvent.

65. The process of compound of claim 63 or 64, wherein the polar solvent is a ketone solvent or an alcohol solvent.

66. The process or compound of any one of claims 58-65, wherein the slurry solvent system comprises at least one polar solvent selected from the group consisting of ethanol, acetone, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), cyclohexanone, cyclopentanone, methanol, isopropanol, tert-butanol, and pentanol.

67. The process or compound of any one of claims 58-66, wherein the slurry solvent system comprises one solvent and the solvent is acetone or MEK.

68. The process or compound of claim 67, wherein the solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

69. The process or compound of claim 68, wherein the ratio of MEK to MIBK is about 4:1 by volume.

70. The process or compound of any one of claims 58-67, wherein the enantiomerically enriched N-protected (-)-cytisine has an enantiomeric excess (ee) of at least about 97%.

71. The process or compound of any one of claims 58-67, wherein the enantiomerically enriched N-protected (-)-cytisine is an enantiomerically enriched N-protected (-)-cytisine salt and has an enantiomeric excess (ee) of at least about 97%.

72. The process or compound of any one of claims 58-70, wherein the enantiomerically enriched N-protected (-)-cytisine has an ee of about 97% to about 99.9%.

73. The process or compound of any one of claims 58-72, wherein the wherein the enantiomerically enriched N-protected (-)-cytisine is an enantiomerically enriched N-protected (-)-cytisine salt and has an ee of about 97% to about 99.9%.

74. An N-protected (-)-cytisine salt that is N-protected (-)-cytisine dibenzoyl-L-tartrate.

75. A process for improving the enantiomeric purity of a N-protected (-)-cytisine salt, comprising:suspending the N-protected (-)-cytisine salt in a slurry solvent system to provide a N-protected (-)-cytisine salt slurry;mixing the N-protected (-)-cytisine salt slurry; andisolating an enantiomerically enriched N-protected (-)-cytisine salt from the slurry.

76. The process of claim 75, wherein the N-protected (-)-cytisine salt has an ee of about 90% to about 96%.

77. The process of claim 75 or 76, wherein the slurry solvent system comprises MEK and MIBK in a ratio of from about 1 :6 to about 6:1 by volume (MEK:MIBK).

78. The process of claim 77, wherein the ratio of MEK to MIBK is about 4:1 by volume.

79. The process of any one of claims 75-78, wherein the enantiomerically enriched N-protected (-)-cytisine salt has an enantiomeric excess (ee) of at least about 97%.

80. The process of any one of claims 75-79, wherein the enantiomerically enriched N-protected (-)-cytisine salt has an ee of about 97% to about 99.9%.

81. The process of any one of claims 75-80, wherein the N-protected (-)-cytisine salt is N-protected (-)-cytisine dibenzoyl-L-tartrate or N-protected (-)-cytisine dibenzoyl-D-tartrate.

82. The process of claim 81 , wherein the N-protected (-)-cytisine salt is (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate.

83. A process for preparing (1 R,5S)-N-benzylcytisine from N-benzyl-(rac)-cytisine, the process comprising resolving the N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

84. A (1 R,5S)-N-benzylcytisine salt prepared by resolving N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid.

85. The process or salt of claim 83 or 84, wherein resolving the N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid comprises combining N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid in a solvent system.

86. A process for resolving N-benzyl-(rac)-cytisine, comprising:combining N-benzyl-(rac)-cytisine with dibenzoyl-L-tartaric acid in a solvent system; andforming (1 R,5S)-N-benzylcytisine.

87. An (1 R,5S)-N-benzylcytisine salt that is (1 R,5S)-N-benzylcytisine dibenzoyl-L-tartrate.